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Prevalence of Autism Spectrum Disorders —
Autism and Developmental Disabilities Monitoring Network,
Six Sites, United States, 2000
Autism and Developmental Disabilities Monitoring Network Surveillance Year 2000 Principal Investigators
Abstract
Problem/Condition: Data from a population-based, multisite surveillance network were used to determine the preva-
lence of children aged 8 years with autism spectrum disorder (ASD) in six areas of the United States and to describe the
characteristics of these children.
Reporting Period: 2000.
Methods: Children aged 8 years were identified as having an ASD through screening and abstraction of evaluation
records at multiple sources, with clinician review of abstracted records to determine case status. Children whose parent(s)
or legal guardian(s) resided in one of the six surveillance areas during 2000 and whose records documented behaviors
consistent with the American Psychiatric Association’s criteria for diagnosing 1) autistic disorder, 2) pervasive develop-
mental disorder-not otherwise specified, or 3) Asperger disorder were classified as having an ASD.
Results: For 2000, across six sites, a total of 1,252 children aged 8 years were identified as having an ASD. The overall
prevalence of ASDs per 1,000 children aged 8 years ranged from 4.5 in West Virginia to 9.9 in New Jersey. With the
exception of one surveillance site (Georgia), no statistically significant (p<0.05) differences were identified in the rate of
ASDs between non-Hispanic black and non-Hispanic white children. The ratio of male-to-female prevalence varied
(range: 2.8:1.0–5.5:1.0). The majority of children with ASDs received special education services and had a documented
history of concerns regarding their development before age 3 years. The prevalence of children with a previously docu-
mented ASD classification varied across sites, but the median age of earliest documented ASD diagnosis was similar across
sites (age 52–56 months). For three sites with sufficient data on intelligence quotient (IQ), cognitive impairment (i.e., IQ
of <70) was reported for 40%–62% of children whose conditions were consistent with the case definition for ASD.
Interpretation: Findings from this first U.S. multisite collaborative study to monitor ASD prevalence demonstrated
consistency across the majority of sites, with prevalence statistically significantly (p<0.001) higher in New Jersey.
Average ASD prevalence across all six sites was 6.7 per 1,000 children aged 8 years. These results indicate that ASDs are
more common than was believed previously.
Public Health Actions: Collecting data regarding prevalence of ASDs by associated characteristics (e.g., cognitive
impairment, age of first documented concerns, and history of ASD diagnosis), race/ethnicity, and sex will provide
important baseline standards that can be compared with follow-up surveillance data to track changes in ASD preva-
lence. Knowledge of these characteristics has implications for identification and intervention strategies and for medical
and educational service planning for children with ASDs.
* In this report, ASD is used to refer to autistic disorder; pervasive
developmental disorder, not otherwise specified (PDD-NOS); and
Asperger disorder. The terms ASD and autism are used interchangeably.
Introduction
Persons with an autism spectrum disorder (ASD)* have
impairments in social, communicative, and behavior devel-
opment that typically are present before age 3 years and that
often are accompanied by abnormalities in cognitive func-
tioning, learning, attention, and sensory processing (1).
Autism was thought previously to be rare, but during the
1990s, the number of persons reported to be receiving ser-
vices for ASDs increased substantially (1–7). This increase has
elevated public concern regarding prevalence of conditions in
the autism spectrum and underscores the need for systematic
public health monitoring. The complex nature of these
behaviorally defined disorders, together with the current lack
of genetic or biologic markers for early and consistent identi-
fication, make epidemiologic investigation challenging (8–10).
Corresponding author: Catherine Rice, PhD, Division of Birth Defects and
Developmental Disabilities, National Center on Birth Defects and Developmental
Disabilities, CDC, 1600 Clifton Road, N.E., MS E-86, Atlanta, GA 30333.
Telephone: 404-498-3860; Fax: 404-498-3550; E-mail: crice@cdc.gov.
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ship, New Jersey (18) and ongoing surveillance in the greater
Atlanta metropolitan area (1,35,36).
In 2000, CDC organized the Autism and Developmental
Disabilities Monitoring (ADDM) Network, a multisite, mul-
tiple-source, records-based surveillance program to collect data
for determining prevalence of ASDs and other developmental
disabilities (9). The ADDM Network, as with CDC’s Atlanta
population-based surveillance program, employs systematic
screening of developmental evaluation records for behaviors
associated with autism rather than depending on a previously
documented diagnosis or classification of autism or a related
disorder to identify children with ASDs (1,9). Because this
methodology collects data from multiple health and service
provision sources rather than from a single source, these data
can be used to estimate a closer approximation of true popula-
tion prevalence than would a single source of special education
or clinical administrative data alone. CDC reports published
previously regarding population-based prevalence of ASDs in
two U.S. communities documented prevalences of 3.4 and 6.7
per 1,000 children aged 3–10 years (1,18). In the larger of these
population studies conducted in Atlanta, the highest prevalence
of ASDs was for children aged 8 years, which is consistent with
observations of peak ASD prevalence among elementary-school–
aged children (26). Therefore, to determine peak prevalence
and evaluate trends, the ADDM Network uses an index age of
8 years. Specified procedures for case identification and reli-
ability among clinician reviewers who verify case status provide
confidence in this methodology (9).
This report presents findings for 2000 from the first six
ADDM Network sites in the United States and establishes a
baseline period prevalence for ASDs by race/ethnicity, sex, and
multiple associated characteristics. Data from the ADDM Net-
work will provide information regarding the clinical features of
children with ASDs in select U.S. populations and make pos-
sible a comprehensive understanding of trends in rates of ASDs.
Knowledge of these characteristics has implications for identi-
fication and intervention strategies and for medical and educa-
tional service planning for children with ASDs.
Methods
Study Sites and Population
Characteristics
CDC and academic researchers at five universities (Table 1)
working on behalf of their state health departments collabo-
rated in identifying the occurrence of ASDs during 2000 in
selected areas of Arizona (one county, including metropolitan
Phoenix), Georgia (five counties in metropolitan Atlanta),
Population-based studies conducted worldwide before 1985
indicated that prevalence of autism and related conditions was
0.4–0.5 per 1,000 children aged <18 years (11–14). The most
recent studies using current Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
(15) and International Classification of Diseases, Tenth Revision
(ICD-10) (16) criteria have identified ASD rates ranging from
2.0 to 12.0 per 1,000 children (1,4,17–23), with “best-estimate”
rates of 2.0–6.0 per 1,000 children (14,24–26). Recent find-
ings reflect the expansion of the definition of autism to encom-
pass a spectrum of disorders that might include co-occurring
mental retardation (MR) or cognitive impairment, and the find-
ings have challenged previously accepted ideas concerning the
population characteristics of persons with ASDs. For example,
certain studies have identified male-to-female ratios twice the
four-to-one male-to-female ratio often identified in older stud-
ies (22) and much lower rates of co-occurring MR (approxi-
mately 25%–50% rather than the typically cited 70%) (21,26).
Studies of ASD prevalence in the United States during the
1990s have identified rates of 2.0–7.0 per 1,000 children (1–3,
5,7,18,27–29), a greater-than-tenfold increase from rates of
0.1–0.4 per 1,000 children identified during the 1980s
(30–32). Certain studies have used data from single-service
provision systems (e.g., numbers of children classified as
having autism for special education or public health disability
services) (2,3,5,7,27,29). Tracking the number of persons iden-
tified for services is important to measure the intervention
needs and costs of care for persons with an identified ASD.
However, because the number of persons identified for ser-
vices is dependant on multiple factors (e.g., changing eligibil-
ity criteria, increased awareness, and changes in service
availability), aggregate data might underestimate prevalence
and should be used with caution in examining population-
based trends (7,8,29,33).
CDC-conducted surveys of parent reports of diagnosed
autism in their children (34) indicated that 5.5–5.7 per 1,000
children aged 4–17 years received a diagnosis of autism dur-
ing 2003–2004, corroborating recent best estimates of
approximately six ASD cases per 1,000 children (14,24–26).
In addition, CDC funds projects that track the number of
children with ASDs, conducts studies to identify what factors
might lead to a child having an ASD, and offers education
and outreach materials for the early identification of autism
and other developmental disabilities. Information regarding
these projects is available at http://www.cdc.gov/autism. To
improve understanding of prevalence, population character-
istics, and the public health impact of these conditions, CDC
also has conducted population-based surveillance projects,
including a community-based investigation in Brick Town-
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Maryland (four counties and Baltimore), New Jersey (four coun-
ties, including metropolitan Newark), South Carolina (23 coun-
ties in the Coastal and PeeDee regions), and West Virginia
(statewide) (Table 1). The number of children aged 8 years
residing in each site during 2000 ranged from 21,532 in Mary-
land to 45,322 in Arizona. The proportion of non-Hispanic
white children was similar across the majority of sites (range:
40% [New Jersey]–54% [Arizona and Maryland]), with the
exception of West Virginia, for which distribution was 93%
(37). Greater variation was reported across sites in the distribu-
tion of non-Hispanic black children (range: 4% [West Virginia]–
47% [South Carolina]). Breakdowns by sex were similar across
sites, with roughly equal distribution of male and female chil-
dren. Sites were chosen by CDC through a competitive objec-
tive review process on the basis of their ability to conduct ASD
surveillance; sites were not selected to reflect a nationally repre-
sentative sample. Each site satisfied local Institutional Review
Board and other privacy and confidentiality requirements.
Surveillance Methods and Case
Definition
The ADDM methodology was adapted from that used by
CDC’s Metropolitan Atlanta Developmental Disabilities Sur-
veillance Program (MADDSP), an ongoing active population-
based surveillance program that monitors the occurrence of
developmental disabilities among children aged 8 years in the
metropolitan Atlanta area (1,9,18,35,36). The ADDM Net-
work implemented the basic MADDSP methodology using
common data abstraction, case definition, clinician review,
and quality assurance procedures (9).
Records of children born in 1992 who had at least one par-
ent or legal guardian who resided in the surveillance area dur-
ing 2000 were reviewed. Children were classified by
clinician reviewers as having an ASD if they displayed behav-
iors from abstracted evaluations during 1992–2000 that were
consistent with DSM-IV-TR criteria for diagnosing 1) autis-
tic disorder; 2) pervasive developmental disorder, not other-
wise specified (PDD-NOS), including atypical autism; or 3)
Asperger disorder (15). Because the number and quality of
ASD criteria specified by DSM-IV-TR are less stringent for
diagnosis of PDD-NOS or Asperger disorder than for autistic
disorder, an additional stricter requirement was added. A
condition was classified as being consistent with an ASD case
status if the criteria for PDD-NOS or Asperger were present
to the extent that at least one of the autism-specific behaviors
was of a sufficient quality or intensity to be highly indicative
of an ASD. For example, in the case definition, the
DSM-IV-TR social criterion of “limited social or emotional
reciprocity” was defined as requiring a specific impairment
(e.g., “rarely responds verbally or nonverbally to a social
approach from others in a familiar setting”). The stricter
requirement for PDD-NOS or Asperger disorder was used
because case status was determined solely on the basis of
information contained in evaluation records. The case defini-
tion focused on identifying the overall presence of an ASD
rather than on attempting to identify specific subtypes of
ASDs. Case determination was completed in two phases: case
ascertainment and clinician review.
Case Ascertainment
Children suspected of having an ASD who satisfied the age,
surveillance year, and residency requirements were identified
through screening source files (1,9) at multiple settings,
including education sources (i.e., public schools†) and health
TABLE 1. Number and percentage of children aged 8 years,* by race/ethnicity and study site — Autism and Developmental
Disabilities Monitoring (ADDM) Network, six sites, United States, 2000
Site Arizona Georgia Maryland New Jersey South Carolina West Virginia
New Jersey
Johns Hopkins Medical Medical University
Site institution University of Arizona CDC University School – Newark of South Carolina Marshall University
4 counties 4 counties in New
1 county, including 5 counties in Maryland plus Jersey, including 23 counties (Coastal
Study area metropolitan Phoenix in metropolitan Atlanta Baltimore City the city of Newark and PeeDee regions) Statewide
Race/Ethnicity No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
White, non-Hispanic 24,564 (54.2) 18,094 (41.5) 11,533 (53.6) 11,913 (40.0) 11,740 (47.9) 21,471 (93.1)
Black, non-Hispanic 2,041 (4.5) 19,232 (44.1) 8,507 (39.5) 7,860 (26.0) 11,607 (47.3) 814 (3.5)
Other† 18,718 (41.3) 6,267 (14.4) 1,492 (6.9) 9,941 (34.0) 1,188 (4.8) 780 (3.4)
Total 45,322 43,593 21,532 29,714 24,535 23,065
Percentage receiving 10.7% 9.9% 10.6% 12.1% 16.9% 16.0%
special education
services
* The total number of children aged 8 years in each study area was obtained from 2000 U.S. Census Bureau files; school districts that did not participate as ADDM data
sources are excluded for three sites (Arizona, Maryland, and New Jersey).
† Includes those classified as Hispanic, American Indian/Alaska Native, Asian/Pacific Islander, or multiracial.
† Educational sources consisted of public education systems in each
surveillance area. Data were not obtained from private schools unless
they were affiliated with one of the health sources or documentation was
kept by the private schools.
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sources (e.g., state health facilities, hospitals, clinics, diagnos-
tic centers, and other clinical providers for children with
developmental disabilities, particularly ASDs) for documented
or suspected ASD classifications and for descriptions of
behaviors associated with ASD diagnostic criteria. At educa-
tional sources, the evaluation records of children receiving
special education services during either the 1999–2000 or the
2000–2001 school year were reviewed. Two sites (West Vir-
ginia during 1999–2000 and Maryland during 2000–2001)
screened records from a single school year, and four sites (Ari-
zona, Georgia, New Jersey, and South Carolina) screened
records from both school years to identify additional cases.
Demographic and exceptionality category for special educa-
tion services, verbatim descriptions of behaviors associated with
autism from evaluations, psychometric test results, develop-
mental history, and evaluation summaries were abstracted from
evaluation records for each child identified as possibly having
an ASD. Screening and abstraction of information in evalua-
tion records was conducted by abstractor staff who met initial
and ongoing reliability standards (9). If information regard-
ing a child was available from multiple sources, data were com-
bined into a composite record. Each child was assigned a study
classification number, and all information abstracted was pro-
tected by multiple confidentiality procedures.
Clinician Review
All abstracted evaluations from the case ascertainment phase
were reviewed and scored by an ASD clinician reviewer (i.e., a
qualified diagnostician with an advanced degree and/or certi-
fication in the assessment and diagnosis of children with
developmental disabilities, especially ASDs). The clinician
reviewer used a coding guide developed on the basis of DSM-
IV-TR criteria (15) to determine if the child’s condition was
consistent with the ASD case definition. Any statement of an
overall developmental concern or a delay in social skills, lan-
guage, or symbolic play at age <3 years was scored, as were
any indications of behavior regression or a plateau in skill
development. Descriptions of associated features (e.g., odd
responses to sensory stimuli) also were coded. A child was
defined as having a previously documented case of an ASD if
any evaluation contained a diagnosis of an ASD from a pro-
fessional examiner qualified by education and training to evalu-
ate the developmental status of children. Interrater reliability
was established among ASD clinician reviewers to standards
of 80%–85% agreement for individually scored items and 90%
for agreement on overall case status. For ongoing interrater
reliability checks, a random sample of records (10%) was scored
independently by a second reviewer with acceptable (81%–
100%) percentage agreements on final case definition.
Analytic Methods
For each child, race and ethnicity were determined from
information contained in the source records or, if missing,
from birth certificates. Period prevalence estimates were cal-
culated using the denominator of the number of children aged
8 years in the surveillance area during 2000 according to U.S.
Census Bureau estimates. Three sites (in Arizona, Maryland,
and New Jersey) excluded nonparticipating school districts
located in the study area from their population denominator,
and cases identified from health sources in these districts were
excluded from the numerator. Poisson approximation to the
binomial distribution was used to calculate 95% confidence
intervals (CIs) for prevalence rates (38). Prevalence results are
reported per 1,000 children. Race-specific rates used the cat-
egories non-Hispanic white, non-Hispanic black, and other
(which included persons who were Hispanic, Asian/Pacific
Islander, and American Indian/Alaska Native). Chi-square
analyses were used, and a p value of <0.05 was used for all
tests of statistical significance.
To assess whether screening special-education files from a sec-
ond school year might improve detection, two sites (Maryland
and West Virginia) linked electronic records from the school
year that were screened to an additional list of children receiv-
ing special education. This procedure was based on the assump-
tion that the probability of identifying a child with a confirmed
case of ASD from the school records screened would apply to
those children who were identified through a second screening
of education files. At each site, certain school and clinical records
could not be located for screening, and the potential impact of
these missing records on case ascertainment was assessed. For
children who did have records to screen, a percentage case yield
was calculated by the type of data source (i.e., education only,
health only, or both education and health) and the presence of
an ASD classification code (i.e., a diagnostic or special educa-
tion eligibility code for ASD). To estimate the impact of miss-
ing records on final prevalence estimates, the percentage of case
yield from the records identified was applied to the children for
whom all or partial records were missing.
Results
Case Ascertainment
Across sites, the percentage of children with an ASD identi-
fied exclusively at educational sources ranged from 22% to
80%, and the percentage identified only at health sources
ranged from 2% to 34%. Those identified at both educational
and health sources ranged from 17% to 65% (Figure 1). The
median number of evaluations abstracted for each child dif-
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fered across sites, ranging from two (Georgia and Maryland)
to eight (New Jersey) for those with an ASD and from one
(Georgia, Maryland, and West Virginia) to five (New Jersey)
for those without an ASD. The proportion of reviewed records
abstracted to the population of children aged 8 years in each
surveillance area ranged from 0.8% to 2.9%. With the excep-
tion of two sites (New Jersey and West Virginia), a strong
inverse correlation was observed between the percentage of
the total number of children abstracted and those classified as
having an ASD (Figure 2). In New Jersey, the final case count
was higher than expected on the basis of the population
abstracted, whereas the reverse was true for West Virginia.
Analyses were conducted for Maryland and West Virginia to
evaluate possible missed cases attributable to screening a single
year of special education data; the results of these analyses
indicated that an estimated 17 cases would have been added
for Maryland and an estimated 14 for West Virginia as a
result of screening a second year of data. The estimated
impact on prevalence of the files that could not be located for
initial screening (i.e., the percentage of missed cases) varied
(range: 3.4% [Georgia]–16.7% [Maryland]).
Prevalence Estimates
and Demographics
Across the six sites, the prevalence of ASDs ranged from 4.5
to 9.9 per 1,000 children aged 8 years (Table 2, Figure 3).
Three sites had similar overall prevalence estimates: 6.3 per
1,000 population in South Carolina and 6.5 per 1,000 in
Arizona and Georgia. The Maryland estimate (5.5 per 1,000
population) did not differ significantly from each of these three
midrange estimates (p = 0.223, 0.112, and 0.105, respectively),
whereas the West Virginia estimate (4.5 per 1,000 popula-
tion) was significantly lower (p = 0.001, 0.006, and 0.001,
FIGURE 1. Percentage of children aged 8 years identified as
having an autism spectrum disorder, by data source —
Autism and Developmental Disabilities Monitoring Network,
six sites, United States, 2000
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FIGURE 2. Percentage of children aged 8 years for whom
records were abstracted and percentage of those abstracted
classified as meeting the case definition* for autism spectrum
disorder (ASD), by site — Autism and Developmental
Disabilities Monitoring Network, six sites, United States, 2000
* Children born in 1992 who had at least one parent or legal guardian who
resided in the surveillance area during 2000 were classified by clinician
reviewers as having an ASD if they displayed behaviors from abstracted
evaluations during 1992–2000 that were consistent with Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria
for diagnosing 1) autistic disorder; 2) pervasive developmental disorder, not
otherwise specified, including atypical autism; or 3) Asperger disorder (15).
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respectively). However, when the impact of screening only
1 year of special education records for Maryland and West
Virginia was taken into account, prevalence estimates for these
sites increased to an estimated 6.3 per 1,000 population (CI =
5.3–7.4) for Maryland and 5.1 (CI = 4.2–6.1) for West Vir-
ginia. Estimated prevalence for New Jersey (9.9 per 1,000
population) was significantly higher (p<0.001) than those for
all other sites.
Across sites, prevalence estimates exhibited heterogeneity by
race/ethnicity. Within-site comparisons demonstrated a sig-
nificant difference in ASD prevalence between non-Hispanic
white and non-Hispanic black children only in Georgia, and
only among males. Sex-specific ASD prevalence ranged from
6.6 to 14.8 for males and from 2.0 to 4.3 for females. The
lowest male-to-female ratio was 2.8:1.0 (South Carolina and
West Virginia); the highest was 5.5:1.0 (Georgia) (Table 2).
Prevalence was based on period prevalence estimates of ASDs
for children aged 8 years who resided in their respective sur-
veillance areas during 2000. The proportion of children with
ASDs who also were born in the surveillance areas was 67%
in Arizona, 54% in Georgia, 77% in Maryland, 84% in New
Jersey, 66% in South Carolina, and 81% in West Virginia.
Special Education Eligibility
The estimated proportion of children aged 8 years with
ASDs receiving special education services through public
6 MMWR February 9, 2007
schools ranged from 70.3% in Maryland to 97.3% in Ari-
zona (Table 3). Across sites, the proportion of children with
ASDs receiving special education services with an autism eli-
gibility classification ranged from 27% in South Carolina to
59% in Georgia.
FIGURE 3. Overall prevalence of autism spectrum disorders
(ASDs) per 1,000 children aged 8 years and prevalence of
children aged 8 years classified as meeting the case definition*
for ASD and having a previous ASD classification — Autism
and Developmental Disabilities Monitoring Network, six sites,
United States, 2000
* Children born in 1992 who had at least one parent or legal guardian
who resided in the surveillance area during 2000 were classified by
clinician reviewers as having an ASD if they displayed behaviors from
abstracted evaluations during 1992–2000 that were consistent with
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision  criteria for diagnosing 1) autistic disorder; 2) pervasive
developmental disorder, not otherwise specified, including atypical
autism; or 3) Asperger disorder (15).
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TABLE 2. Estimated prevalence* of autism spectrum disorders (ASDs) among children aged 8 years, by race/ethnicity† — Autism
and Developmental Disabilities Monitoring (ADDM) Network, six sites, United States, 2000
                     No. children
          aged 8 yrs Prevalence
Total Total White, Black, White-to- Male-to-
in study with Overall
§ non–Hispanic non–Hispanic black Male Female female
Site area** ASDs Rate (95% CI††) Rate (95% CI) Rate (95% CI) ratio Rate (95% CI) Rate (95% CI) ratio¶
Arizona 45,322 295 6.5 (5.8–7.3) 8.6 (7.5–9.8) 7.3 (4.4–12.2) 1.2 9.7 (8.5–11.1) 3.2 (2.5–4.0) 3.0
Georgia 43,593 285 6.5 (5.8–7.3) 7.9 (6.7–9.3) 5.3 (4.4–6.4) 1.5§§ 11.0 (9.7–12.4) 2.0 (1.5–2.7) 5.5
Maryland 21,532 118 5.5¶¶ (4.6–6.6) 4.9 (3.8–6.4) 6.1 (4.7–8.0) 0.8 8.6 (7.1–10.6) 2.2 (1.5–3.3) 3.9
New Jersey 29,714 295 9.9 (8.9–11.1) 11.3 (9.5-13.3) 10.6 (8.5-13.1) 1.1 14.8 (13.0–16.8) 4.3 (3.3–5.5) 3.4
South Carolina 24,535 155 6.3 (5.4–7.4) 6.5 (5.2–8.2) 5.8 (4.5–7.3) 1.1 9.3 (7.8–11.2) 3.3 (2.4–4.5) 2.8
West Virginia 23,065 104 4.5¶¶ (3.6–5.4) 4.5 (3.7–5.5) *** 6.6 (5.2–8.2) 2.4 (1.6–3.5) 2.8
* Per 1,000 children aged 8 years in surveillance area.
† Because of limited sample sizes, only two racial/ethnic populations are presented.
§ All children are included in the total regardless of race/ethnicity. The total also includes children whose race is unknown.
¶ All male-to-female ratios differed significantly (p<0.0001) within sites.
** The total number of children aged 8 years in each ADDM surveillance area was obtained from 2000 U.S. Census Bureau files; surveillance areas exclude school districts
that did not participate as data sources for three sites (Arizona, Maryland, and New Jersey).
†† Confidence interval.
§§ White-to-black prevalence ratios differed significantly (p<0.05) within sites only for Georgia.
¶¶ Adjusted ASD prevalence for Maryland and West Virginia also were calculated to account for having a single year of educational records screened for these two sites
compared with 2 years of educational records for the other four sites. The adjusted rates per 1,000 children aged 8 years were 6.3 (95% CI = 5.3–7.4) for Maryland and 5.1
(95% CI = 4.2–6.1) for West Virginia.
*** Prevalence and white-to-black ratio not reported because of limited sample size.
Previously Documented Classification
of ASDs
Children with a previously documented ASD classification
included children who received special education services
under an autism special education eligibility and those docu-
mented in the source records as having an ASD diagnosis. Preva-
lence estimates per 1,000 population derived for children with
an ASD with a previous ASD classification were 3.1 in Arizona
and South Carolina, 3.6 in West Virginia, 3.9 in Maryland, 4.6
in Georgia, and 6.8 in New Jersey. For all sites, ASD prevalence
calculated on the basis of a child having received a previous
classification of ASD was significantly (p<0.05) lower than
prevalence estimated using the ADDM Network methodology,
with the exception of West Virginia (Figure 3).
TABLE 3. Number and percentage of children aged 8 years
with autism spectrum disorders (ASDs) receiving special
education services and having autism eligibility* — Autism
and Developmental Disabilities Monitoring Network, six sites,
United States, 2000
Receiving Receiving
special special education
education services with
Total no. services  autism eligibility*
Site with ASDs No. (%) No. (%)
Arizona 295 287 (97.3) 91 (31.7)
Georgia 285 261 (91.6) 155 (59.4)
Maryland 118 83 (70.3) 36 (48.6)
New Jersey 295 282 (95.6) 118 (41.8)
South Carolina 155 130 (83.9) 36 (27.7)
West Virginia 104 96 (92.3) 45 (46.9)
* The primary category under which a child was receiving special
education services in the public schools.
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Developmental Characteristics
Cognitive functioning as indicated by IQ findings is reported
for the three sites in which >85% of children had psychomet-
ric test results: Arizona with 90%, Georgia with 94%, and
South Carolina with 89%. Of the children with ASDs who
had a cognitive or developmental IQ test result, the propor-
tion of children with cognitive impairment (IQ of <70) was
46% (N = 123) in Arizona, 40% (N = 107) in Georgia, and
62% (N = 86) in South Carolina. The distribution of cogni-
tive functioning in females was similar across sites. The pro-
portion of males with cognitive impairment ranged from 36%
in Georgia to 61% in South Carolina, and the proportion of
males with average or above-average cognitive functioning (i.e.,
IQ of >85) ranged from 17% in South Carolina to 39% in
Arizona (Figure 4).
The majority (69%–88%) of children with ASDs had docu-
mented developmental concerns before age 3 years. Across all
sites, the most commonly documented early developmental
concern was for language, followed by social concerns. Docu-
mented developmental concerns with imaginative play were
least common across all sites (Table 4). The median age of
earliest reported ASD diagnosis identified in the child’s record
was similar (range: 52–56 months) across sites (Table 5). The
percentage of children with indications of regression (loss of
previously acquired skills in social, communication, play, or
motor areas) and plateau (lack of continued development with-
out clear evidence of regression) in records ranged from 13%
to 27% and 3% to 8%, respectively, across sites (Table 5).
The median age of regression ranged from 23 to 26 months.
Discussion
Because ASDs are diagnosed on the basis of behavioral cri-
teria, and clinicians might apply criteria differently to arrive
at a diagnosis of autism and related subtypes, determining
FIGURE 4. Intelligence quotient (IQ) of children aged 8 years
with an autism spectrum disorder for whom psychometric
test data were available, by site and sex — Autism and
Developmental Disabilities Monitoring Network, three sites,
United States, 2000
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TABLE 4. Number and percentage of children aged 8 years with autism spectrum disorder with developmental concerns* noted
before age 3 years, by concern — Autism and Developmental Disabilities Monitoring Network, six sites, United States, 2000
Total
no. with General concern Social Language Imaginative play
Site ASDs No. (%) No. (%) No. (%) No. (%)
Arizona 295 260 (88.1) 90 (30.5) 240 (81.4) 11 (3.7)
Georgia 285 218 (76.5) 91 (31.9) 190 (66.7) 38 (13.3)
Maryland 118 81 (68.6) 24 (20.3) 66 (55.9) 9 (7.6)
New Jersey 295 237 (80.3) 71 (24.1) 233 (79.0) 16 (5.4)
South Carolina 155 128 (82.6) 47 (30.3) 112 (72.3) 33 (21.3)
West Virginia 104 73 (70.2) 36 (34.6) 68 (65.4) 14 (13.5)
* For each child, all evaluation information was reviewed to categorize any concerns noted in developmental evaluations concerning the child’s
developmental status before age 3 years; any specified concerns regarding the development of social, language, or imaginative play before age 3
years also were documented.
TABLE 5. Median age at earliest diagnosis of autism spectrum disorder (ASD) and proportion and median age of children with a
confirmed ASD at age 8 years with developmental regression or plateau noted in records — Autism and Developmental Disabilities
Monitoring Network, six sites, United States, 2000
Earliest documented diagnosis Regression Plateau
Median age Range Median age Range Median age Range
Site (mos) (mos) (mos) (mos) (%) (mos) (mos)  (%)
Arizona 53 21–106 24 6–81 (12.5) 24 6–77 (7.8)
Georgia 56 17–103 24 1–91 (17.2) 24 6–72 (7.7)
Maryland 54 26–93 26 9–70 (20.3) 29 18–36 (6.8)
New Jersey 52 12–104 24 2–77 (23.7) 18 6–58 (6.4)
South Carolina 54 24–100 24 9–66 (19.4) 15 12–18 (2.6)
West Virginia 52 24–100 23 7–101 (26.9) 24 18–36 (4.8)
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prevalence is challenging (1,8,9). The ADDM Network sur-
veillance approach involved collecting detailed behavior data
from multiple data sources regarding a substantial number of
children with indications of a potential ASD. This methodol-
ogy minimized reliance on a child’s previously documented
diagnoses or special education eligibility category to classify a
child as having an ASD. Applying the ADDM Network
approach in six areas of the United States generated ASD preva-
lence estimates for children aged 8 years ranging from 4.5 to
9.9 per 1,000 children aged 8 years. The estimate for West
Virginia (4.5 per 1,000 children aged 8 years) was signifi-
cantly lower, and the estimate for New Jersey (9.9 per 1,000
children aged 8 years) was significantly higher, than the mid-
range estimates. The average prevalence of 6.7 per 1,000 chil-
dren aged 8 years identified in this report is consistent with
the upper end of prevalence (5.8–6.7 per 1,000 children) from
epidemiologic studies using active population screening and
clinical case confirmation within the preceding 10 years
(18–21). However, the significantly higher prevalence from
New Jersey also was in line with a few studies indicating higher
ASD rates (11.6 and 12.1 per 1,000 children aged 7–10 years)
(22,39). The higher rate of ASDs in children aged 8 years in New
Jersey indicates the importance of continuing to evaluate com-
munity variation and trends in prevalence in the United States.
ASD prevalence among children aged 8 years varied from
6.6 to 14.8 per 1,000 boys and from 2.0 to 4.3 per 1,000
girls. The male-to-female ratio (2.8:1.0–5.5:1.0) is consistent
with previous literature indicating an average male-to-female
ratio of 4.3:1.0 (26). Although a limited number of studies
have reported race-specific ASD prevalence, the available data
are inconsistent. Administrative data from California suggest
a slightly higher prevalence in black than in white children
(40), but a previous report from Georgia indicated a similar
prevalence for black and white children (1). An analysis of
claims data from Pennsylvania Medicaid recipients receiving
services for autistic disorder demonstrated that being white
was associated with receiving a first diagnosis at an earlier age
(41), which might affect age-specific prevalence estimates
and reflect access to diagnostic services. In this report, the
confidence intervals for race-specific prevalence estimates over-
lapped considerably, with the exception of Georgia.
The proportion of children with ASDs who had cognitive
impairment (IQ <70) ranged from 40% to 62% in the three
sites for which IQ data were available. Children with ASDs in
South Carolina, particularly males, were more likely to be clas-
sified with cooccurring cognitive impairment compared with
children with ASDs in Arizona and Georgia. Females showed
a similar distribution in level of cognitive impairment across
these three sites, with the majority of females with ASDs also
having cooccurring cognitive impairment. These proportions
are below the 75% of children having cognitive impairment
typically reported in earlier epidemiologic in which cases were
identified solely on the basis of autistic disorder (26) but above
estimates from studies conducted during the 1990s using
active screening to identify all ASD cases (20,22). If these
data are accurate, additional high-functioning children with
ASDs might remain unidentified. Children with a very mild
ASD might not be counted because inclusion in this system
required that the child was evaluated for special educational
or health-care needs. Variation exists in the proportion of chil-
dren in the population identified for special education across
study areas (Table 1); however, a clear pattern does not exist
in which sites that identified more children for special educa-
tion in the base population ultimately had a higher or lower
prevalence of ASD.
Early identification and participation in intervention can
improve the long term outcome for children with an ASD
(42). The majority of children identified in these six sites
received diagnostic evaluations that noted developmental con-
cerns before age 3 years, primarily in the development of lan-
guage skills; 11%–27% lost developmental skills at a young
age (median age: 23–26 months); and 3%–8% demonstrated a
plateau in development that was substantial enough to be
reported in a developmental evaluation. The median age of the
first documented ASD diagnosis was age 52–56 months. CDC
has been working with caregiver and professional groups to
improve the recognition of developmental concerns and to
improve referral for further evaluation and intervention with the
“Learn the Signs. Act Early.” public awareness campaign (43).
As noted previously (1), the ability to access information
from sources outside clinical sources typically utilized for public
health surveillance sources is critical to the success of a records-
based ASD monitoring effort. For example, a substantial pro-
portion (range: 22%–80%, depending on site) of the children
with a reported ASD would not have been identified without
educational data. In addition, a proportion of those identi-
fied from a combination of educational and health data (range:
17%–65%, depending on site) also would have been missed
if the information from educational sources had been unavail-
able. The added benefit of educational records in the moni-
toring system is derived primarily from the detailed behavior
data in the evaluations contained in school records rather than
the single label provided by a special education classification.
As previous studies have indicated, reliance on special educa-
tion classification alone to estimate population autism preva-
lence is problematic (7,30,33). In five of the six ADDM
Network sites, less than half (as low as 27%) of the children
with a confirmed ASD were served under an autism special
education classification. Prevalence estimates derived from
using a documented previous ASD classification as the
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numerator ranged from 20% in West Virginia to 52% in South
Carolina, lower than the estimates derived by using the ADDM
Network monitoring approach (Figure 3).
One strength of the ADDM Network is its consistency of
data collection and case determination across sites. The surveil-
lance methodology uses standardized abstractor and clinician
reviewer training, ongoing quality assurance monitoring, and
similar standards to identify and confirm potential cases and to
analyze data (9,44). Although the proportion of reviewed records
abstracted in each surveillance area ranged from 0.8% to 2.9%,
sites with a higher percentage of abstracted records actually had
lower percentages of confirmed cases. This suggests that the
standardized methods used for clinical review resulted in con-
sistent application of the case definition across sites (Figure 2).
Although the intent of the ADDM Network sites was to
use comparable methods, multiple sources of variability might
be responsible for differences in prevalence across study sites.
These include variation in state standards for evaluation and
classification of children with ASDs, exclusion of certain
sources (e.g., private schools), use of special education child
count data from one rather than two school years, and inabil-
ity to locate source files. Sites also varied in the percentage of
records abstracted and in the quantity and quality of infor-
mation available in some of the abstracted files. Because the
ADDM methodology is records-based, the number and con-
tent of the records abstracted at any site could influence preva-
lence estimation. All ADDM sites included public schools and
the major developmental disabilities evaluation and treatment
centers serving their surveillance areas as sources of records.
The effect of excluding private schools, charter schools, and
smaller clinical providers on prevalence estimates is difficult
to quantify but might have contributed to underestimation
of prevalence, except for New Jersey, whose school system
maintains records and evaluations for children receiving spe-
cial education who attend nonpublic schools. Behavior
descriptions contained in educational and health records might
have overstated or understated autism symptoms; in addition,
the information available probably was not complete enough
to allow reviewers to determine whether a possible case was
consistent with ASD criteria.
A limitation of using a records-based approach is that the
amount and quality of information available varied across sites.
Two sites (Maryland and West Virginia) screened special edu-
cation files from one rather than two school years, which
appears to account, in part, for the lower prevalence rates from
these sites. After the impact of screening 1 year rather than
2 years of special education data was taken into account, preva-
lence estimates from Maryland and West Virginia (6.3 and
5.1 per 1,000 children aged 8 years, respectively) were similar
to the majority of the other sites. One factor that affected all
sites was the number of files not located at data sources dur-
ing the case-ascertainment phase. Sensitivity analyses con-
ducted by all sites to determine the effect of files that were not
located indicated a possible prevalence underestimation of
3.4% to 16.7%, with the greatest impact in Maryland.
Among children whose case status was consistent with the
ASD case definition, the median number of evaluations iden-
tified and abstracted for each child from birth to age 8 years
ranged from two each in Georgia and Maryland to eight in
New Jersey. Among children without ASDs, the median num-
ber of evaluations abstracted for each child ranged from one
each in Georgia and Maryland to five in New Jersey. A quali-
tative review of each site’s records indicates that in addition to
New Jersey having the greatest number of evaluations per child,
New Jersey evaluation records also contained more detailed
information. In certain cases, the availability of information
in records might have been affected by state law or by local
school regulations. For example, New Jersey frequently
employed multidisciplinary evaluations to confirm eligibility
for special education, which might have resulted in more evalu-
ations per child compared with sites for which a single evalu-
ation was used to determine eligibility. Also, the substantial
difference in the presence of cognitive functioning data on
cases is a byproduct primarily of state policy regarding cogni-
tive testing (e.g., in Arizona, Georgia, and South Carolina, all
children with an autism exceptionality are required to have an
IQ test, whereas no such requirement exists in New Jersey,
Maryland, and West Virginia).
Another factor possibly contributing to variation in esti-
mates is differential in- and out-migration in these six areas
because prevalence estimates in this report are period preva-
lence estimated on the basis of residency in the study area
during 2000. Although the reasons why families might have
moved in or out of the study area could not be determined,
the proportion of children with ASDs who were born in the
study areas ranged from 54% in Georgia to 84% in New Jer-
sey, indicating a potential for differential migration patterns
in the sites. However, the high proportion of children with
ASDs that were born in the New Jersey surveillance area
compared with the other sites indicates that differential
in-migration might not be a substantial contributor to New
Jersey’s higher prevalence of ASDs.
Etiologic differences also might contribute to across-site
variation in prevalence. Conclusions about specific etiologic
factors cannot be drawn from prevalence data alone and will
need to be addressed through future studies. For example,
following concern about high prevalence of ASD in Brick
Township, New Jersey (18), an investigation was conducted
to assess specific environmental exposures in that township,
and no specific associations were identified between hazard
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exposure from the municipal drinking water supply, town river,
or landfill and ASD cases (45). In addition to better under-
standing of consistency and variance in ASD prevalence in
different U.S. communities, specific studies are needed to
investigate the complex genetic and environmental interac-
tions likely at play in the development of heterogeneous con-
ditions such as ASDs.
The initial findings presented in this report are derived from
data collected by the first comprehensive U.S. monitoring
network devoted to ASDs. Prevalence of ASDs in five of the
six sites was consistent with the upper end of recent commu-
nity and survey-based epidemiologic study estimates
(1,17,18,20,21,34,46), and one site demonstrated a signifi-
cantly higher (p<0.001) prevalence similar to two non-U.S.
studies (22,39). These findings indicate that ASDs are more
common than were once believed and are conditions of
urgent public health concern. Since its inception, the ADDM
Network has expanded to include additional sites that will
continue to provide baseline ASD prevalence data and
descriptive information regarding the ASD population in the
United States. Ongoing surveillance to monitor trends in ASD
prevalence and studies that include clinical validation of cases
and noncases will be particularly useful for furthering the
understanding of the prevalence of ASDs and of the charac-
teristics of persons with ASDs.
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Prevalence of Autism Spectrum Disorders —
Autism and Developmental Disabilities Monitoring Network,
14 Sites, United States, 2002
Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators
Abstract
Problem/Condition: Data from a population-based, multisite surveillance network were used to determine the preva-
lence of autism spectrum disorders (ASDs) among children aged 8 years in 14 areas of the United States and to describe
the characteristics of these children.
Reporting Period: 2002.
Methods: Children aged 8 years were identified as having an ASD through screening and abstraction of evaluation
records at health facilities for all 14 sites and through information from psychoeducational evaluations for special
education services for 10 of the 14 sites. Case status was determined through clinician review of data abstracted from
the records. Children whose parent(s) or legal guardian(s) resided in the respective areas in 2002 and whose records
documented behaviors consistent with the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-
TR) criteria for autistic disorder; pervasive developmental disorder, not otherwise specified; or Asperger disorder were
classified as having ASDs.
Results: For 2002, of 407,578 children aged 8 years in the 14 surveillance areas, 2,685 (0.66%) were identified as
having an ASD. ASD prevalence per 1,000 children aged 8 years ranged from 3.3 (Alabama) to 10.6 (New Jersey), with
the majority of sites ranging from 5.2 to 7.6 (overall mean: 6.6 [i.e., one of every 152 children across all sites). ASD
prevalence was significantly lower than all other sites in Alabama (p<0.001) and higher in New Jersey (p<0.0001).
ASD prevalence varied by identification source, with higher average prevalence for ASDs in sites with access to health
and education records (mean: 7.2) compared with sites with health records only (mean: 5.1). Five sites identified a
higher prevalence of ASDs for non-Hispanic white children than for non-Hispanic black children. The ratio of males
to females ranged from 3.4:1.0 in Maryland, South Carolina, and Wisconsin to 6.5:1.0 in Utah. The majority of
children were receiving special education services at age 8 years and had a documented history of concerns regarding
their development before age 3 years. However, the median age of earliest documented ASD diagnosis was much later
(range: 49 months [Utah]–66 months [Alabama]). The proportion of children with characteristics consistent with the
criteria for an ASD classification who had a previously documented ASD classification varied across sites. In the
majority of sites, females with an ASD were more likely than males to have cognitive impairment. For the six sites for
which prevalence data were available from both 2000 and 2002, ASD prevalence was stable in four sites and increased
in two sites (17% in Georgia and 39% in West Virginia).
Interpretation: Results from the second report of a U.S. multisite collaboration to monitor ASD prevalence demon-
strated consistency of prevalence in the majority of sites, with variation in two sites. Prevalence was stable in the
majority of sites for which 2 years of data were available, but an increase in West Virginia and a trend toward an increase
in Georgia indicate the need for ongoing monitoring of ASD prevalence.
Public Health Actions: These ASD prevalence data provide the most complete information on the prevalence of the
ASDs in the United States to date. The data confirm that ASD prevalence is a continuing urgent public health concern
affecting an approximate average of one child in every 150 and that efforts are needed to improve early identification
of ASDs.
Introduction
Persons with autism spectrum disorder (ASDs)* have
impairments in social, communicative, and behavior devel-
* In this report, ASD is used to refer to autistic disorder; pervasive
developmental disorder, not otherwise specified (PDD-NOS); and
Asperger disorder. The terms ASD and autism are used interchangeably.
Corresponding author: Catherine Rice, PhD, Division of Birth Defects and
Developmental Disabilities, National Center on Birth Defects and Developmental
Disabilities, CDC, 1600 Clifton Road, N.E., MS E-86, Atlanta, GA 30333.
Telephone: 404-498-3860; Fax: 404-498-3550; E-mail: crice@cdc.gov.
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opment that typically are identified before age 3 years, often
accompanied by abnormalities in cognitive functioning, learn-
ing, attention, and sensory processing (1). ASDs represent a
spectrum of behaviorally defined conditions that are diagnosed
through clinical observation of development. The complex
nature of these behaviorally defined disorders, coupled with
the current lack of genetic or biologic markers for early and
consistent identification, make epidemiologic investigation
challenging.
Although autism was defined previously primarily as autis-
tic disorder and thought to be rare, autism is now considered
one of multiple ASDs (2,3). During the 1990s, the number
of persons reported to be receiving services for ASDs increased
substantially (4–9). In California, the number of persons
receiving services for autism increased approximately 300%
during 1987–1998 and approximately 100% during 1998–
2002 (4,5). After adjusting for changes in population size,
prevalence for persons in the 1987–1994 birth cohorts
receiving autism services in California increased from 0.6 to
1.5 per 1,000 population (6). In Minnesota, steady increases
have been demonstrated in the prevalence of diagnosed
autism among three birth cohorts (7); prevalence in children
aged 8 years increased from 2.0 per 1,000 population in the
1997–1998 school year to 6.6 per 1,000 population in the
2001–2002 school year. Nationwide, the number of children
receiving special education services for autism increased 500%
from the 1991–1992 school year to the 1998–1999 school
year (8). Data comparing the prevalence of autism with other
disabilities for successive birth cohorts of school children
indicated that among children aged 10 years, autism preva-
lence per 1,000 children increased from 0.5 in the 1984 birth
cohort to 1.8 in the 1990 birth cohort; increases were greater
in children aged 6 years, increasing from 0.5 in the 1986 birth
cohort to 2.4 in the 1994 birth cohort (9).
Although more children are being identified with an ASD
than in the past, receipt of educational or intervention services
under an autism classification does not necessarily identify all
persons with the behavioral profile indicative of an ASD and
might not provide an accurate picture of total prevalence in the
population (1,10). Studies that relied exclusively on single-source
administrative data sets (e.g., clinic service records or annual
reports of special education counts) are reportedly problematic
(9,11,12). Single-source service data sets most likely underesti-
mate prevalence and might not adequately capture population
changes over time. Elevated public concern regarding the
increase in reported ASD prevalence underscores the need for
systematic public health monitoring (11,13).
In 2000, CDC organized the Autism and Developmental
Disabilities Monitoring (ADDM) Network, a multisite, mul-
tiple-source, records-based surveillance program to collect data
for determining prevalence of ASDs and other developmental
disabilities (13). The ADDM Network conducts detailed
screening and review of behavioral data from multiple educa-
tional and health facilities concerning children who have been
evaluated for a range of developmental conditions and applies
standard criteria for case identification, ascertainment, and
case classification across multiple surveillance sites. Ongoing
planning and cooperation among ADDM Network programs
has been based on collaboration across multiple disciplines,
organizations, and agencies.
The first study conducted by the ADDM Network reported
results for 2000 from six sites in selected areas of Arizona,
Georgia, Maryland, New Jersey, South Carolina, and West
Virginia and established baseline period prevalence for ASDs
by race/ethnicity and sex and described multiple associated
characteristics (e.g., cognitive impairment) (14). In 2000,
total ASD prevalence per 1,000 children aged 8 years in the
six surveillance sites ranged from 4.5 in West Virginia to 9.9
in New Jersey (overall mean: 6.7). In 2002, to determine the
prevalence of ASDs in additional areas of the United States,
funding was provided to add eight sites in addition to the six
studied previously. This report presents results for 2002 from
the 14 sites studied, describes prevalence for ASDs overall and
by race/ethnicity and sex and provides information concern-
ing multiple associated characteristics. The additional data pro-
vided by the expanded ADDM Network will provide
information regarding the prevalence and population charac-
teristics in a large cohort of children in selected U.S. areas.
Because six of these sites also collected data on ASD preva-
lence in 2000, changes in overall prevalence in these sites also
are reported.
Methods
Study Sites and Population
Characteristics
CDC and 13 project teams at state health departments or
at universities working on behalf of their state health depart-
ments (Table 1) collaborated in monitoring reported occur-
rence of ASDs during 2002 in selected areas of Alabama
(northern 32 counties), Arizona (one county, including met-
ropolitan Phoenix), Arkansas (statewide), Colorado (two coun-
ties in metropolitan Denver), Georgia (five counties in
metropolitan Atlanta), Maryland (five counties, including Bal-
timore City), Missouri (five counties in metropolitan St. Louis)
New Jersey (four counties, including metropolitan Newark),
North Carolina (eight central counties), Pennsylvania (Phila-
delphia County), South Carolina (23 counties in the Coastal
and PeeDee regions), Utah (three counties in the Salt Lake
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TABLE 1. Population characteristics for children aged 8 years, by site — Autism and Developmental Disabilities Monitoring
Network, 14 Sites, United States, 2002
White, Black, Special
Site Surveillance Total no. non-Hispanic non-Hispanic Hispanic AI/AN
† A/PI§ education¶
Site institution area* in area No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Sites with access only to health records
Alabama University of 32 counties 35,472 24,552 (69.2) 9,442 (26.6) 1,046 (2.9) 178 (0.5) 254 (0.7) 5,407 (15.2)
Alabama –
Birmingham
Missouri Washington 5 counties 28,049 19,043 (67.9) 7,817 (27.9) 548 (2.0) 80 (0.3) 561 (2.0) 3,569 (12.7)
University in in metropolitan
St. Louis St. Louis
Pennsylvania University of Philadelphia 21,061 5,795 (27.5) 11,388 (54.1) 2,956 (14.0) 59 (0.3) 863 (4.1) 1,586 (7.5)
Pennsylvania County
Wisconsin University of 10 counties in 35,126 23,893 (68.0) 6,564 (18.7) 3,419 (9.7) 193 (0.5) 1,057 (3.0) 3,764 (10.7)
Wisconsin – Southeastern
Madison Wisconsin,
including
Milwaukee
Sites with access to both education and health records
Arizona University 1 county, 45,113 25,252 (56.0) 2,377 (5.3) 15,348 (34.0) 966 (2.1) 1,169 (2.6) 6,289 (13.9)
of Arizona including
metropolitan
Phoenix
Arkansas University of Statewide 36,472 25,981 (71.2) 7,771 (21.3) 2,074 (5.7) 287 (0.8) 359 (1.0) 3,950 (10.8)
Arkansas for
Medical
Sciences
Colorado Colorado 2 counties 11,020 7,516 (68.2) 933 (8.5) 2,026 (18.4) 67 (0.6) 478 (4.3) 1,258 (11.4)
Department in metropolitan
of Public Denver
Health and
Environment
Georgia CDC 5 counties 44,299 18,038 (40.7) 19,824 (44.8) 4,342 (9.8) 94 (0.2) 2,001 (4.5) 4,483 (10.1)
in metropolitan
Atlanta
Maryland Johns Hopkins 5 counties 29,722 17,100 (57.5) 10,865 (36.6) 735 (2.5) 82 (0.3) 940 (3.2) 2,968 (10.0)
University in Maryland,
including
Baltimore City
New Jersey New Jersey 4 counties, 29,748 12,670 (42.6) 8,020 (27.0) 7,407 (24.9) 76 (0.3) 1,575 (5.3) 2,595 (13.0)
Medical including
School – metropolitan
Newark Newark
North University of 8 central 20,725 12,134 (58.5) 6,284 (30.3) 1,707 (8.2) 80 (0.4) 520 (2.5) 3,014 (14.5)
Carolina North Carolina counties
at Chapel Hill
South Medical 23 counties in 23,191 11,627 (50.1) 10,563 (45.5) 684 (2.95) 95 (0.4) 222 (1.0) 4,309 (18.5)
Carolina University of the coastal and
South Carolina Pee Dee
regions
Utah Utah 3 counties 26,108 21,201 (81.2) 363 (1.4) 3,447 (13.2) 190 (0.7) 907 (3.5) 3,404 (13.0)
Department around
of Health metropolitan
Salt Lake City
West Virginia Marshall Statewide 21,472 20,112 (93.7) 944 (4.4) 245 (1.1) 50 (0.2) 121 (0.6) 3,807 (17.7)
University
Source: Total numbers of children aged 8 years in each surveillance area were obtained from CDC’s National Center for Health Statistics vintage 2004 postcensal population
estimates (13).
* Surveillance area denominators exclude those school districts that did not allow access to records (Arizona and New Jersey).
† American Indian/Alaska Native.
§ Asian/Pacific Islander
¶ Each site provided the count of children in special education as reported by their local or state school districts.
Vol. 56 / SS-1 Surveillance Summaries 15
City metropolitan area), West Virginia (statewide), and Wis-
consin (10 counties in southeastern Wisconsin, including met-
ropolitan Milwaukee). The Missouri site originally included
three counties in Illinois that are considered part of metro-
politan St. Louis, but data from these counties are not pre-
sented because the limited sources of data resulted in
incomplete prevalence estimates. The number of children aged
8 years in the 14 surveillance sites ranged from 11,020 in
Colorado to 45,113 in Arizona.
Distribution according to race or ethnicity among children
aged 8 years varied across surveillance sites (15). The percent-
age of non-Hispanic white children ranged from 27.5% in
Pennsylvania to 93.7% in West Virginia; the percentage of
non-Hispanic black children ranged from 1.4% in Utah to
54.1% in Pennsylvania. The breakdown by sex was similar
across sites, with approximately equal distribution of male and
female children. Sites were selected through a competitive pro-
cess that evaluated their ability to conduct ASD surveillance.
They were not selected to reflect a nationally representative
sample. The population of children studied (approximately
400,000) represented approximately 10% of the U.S. popu-
lation aged 8 years in 2002. Each site met applicable local
Institutional Review Board or other privacy and confidential-
ity requirements, or both. In three sites (Colorado, Utah, and
West Virginia), ASDs were considered reportable conditions
under state public health statute or administrative regulation.
Surveillance Methods and Case
Definition
The methodology used by the ADDM Network was based
on CDC’s Metropolitan Atlanta Developmental Disabilities
Surveillance Program (MADDSP), an active, population-based
surveillance program that monitors the occurrence of develop-
mental disabilities among children aged 8 years in the metro-
politan Atlanta area (1,16,17). The ADDM Network
implemented the basic MADDSP methodology using a com-
mon case definition and standardized data abstraction, clini-
cian review, and quality assurance procedures for the first year
of surveillance in 2000 (13,14). For 2002, the case definition
was modified to incorporate a brief screening, abstraction, and
review of children’s records if the child already had a documented
ASD diagnosis or special education eligibility of autism.
Case Definition
Children born in 1994 who had at least one parent or legal
guardian who resided in the study area during 2002 were clas-
sified by clinician reviewers as having an ASD if they either 1)
had a documented previous classification of an ASD (i.e., the
child had either an uncontradicted record of an autistic disor-
der or ASD diagnosis provided by a qualified examiner or
documentation of qualification for special education services
during 1994–2002 under an autism eligibility category) or 2)
did not have a documented ASD classification but had an
evaluation record from an educational or clinical source indi-
cating unusual social behaviors consistent with an ASD. For
children with a documented previous classification of an ASD,
case status was confirmed on the basis of the existing ASD
classification from the evaluation source records. For children
without a documented ASD classification, data were abstracted
on all pertinent ASD and developmental behaviors from edu-
cation or health developmental evaluation to determine
whether behaviors described in the child’s evaluations by clini-
cal reviewers were consistent with the criteria listed in the
Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR) (2) for autistic disorder,
PDD-NOS (including atypical autism), or Asperger disorder.
Because the number and quality of criteria specified by DSM-
IV-TR are lower for diagnosis of PDD-NOS or Asperger dis-
order than for autistic disorder, an additional stricter
requirement was added that at least one of the autism-specific
behaviors be of a sufficient quality or intensity to be highly
indicative of an ASD (14). For example, in the case defini-
tion, the DSM-IV-TR social criterion of “limited social or
emotional reciprocity” was defined as requiring a specific
impairment (e.g., “rarely responds verbally or nonverbally to
a social approach from others in a familiar setting”). The more
stringent criterion for PDD-NOS or Asperger disorder was
used because case status was determined solely on the basis of
information contained in evaluation records. The case defini-
tion focused on identifying the overall presence of an ASD
rather than on attempting to identify specific subtypes of
ASDs. Case determination was completed in two phases: case
ascertainment and clinician review.
Case Ascertainment
Children suspected of having an ASD who satisfied the age,
surveillance year, and residency requirements were identified
through screening evaluation records (e.g., assessments to
determine the need for special education services or the pres-
ence of a developmental disorder). Records were screened at
multiple educational or health sources (including state health
facilities, hospitals, clinics, diagnostic centers, and other clinical
providers), or at both for documented or suspected ASD
classifications and for descriptions of behaviors associated with
an ASD diagnosis. All sites screened files from health sources
that maintained evaluation records for children with develop-
mental disabilities, particularly ASDs. The files that were
screened were identified by having a diagnostic or billing
International Classification of Diseases, Ninth Revision (ICD-9)
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(18) code for child neurodevelopmental disorders (e.g., speech
and language disorders). All sites were either state health
departments or acted as their heath department representa-
tive to collect or receive information used for protecting pub-
lic health (19). On the basis of site-specific collaboration with
their state and local departments of education, 10 sites (Ari-
zona, Arkansas, Colorado, Georgia, Maryland, New Jersey,
North Carolina, South Carolina, Utah, and West Virginia)
(Table 1) also screened the special education evaluation records
retained by schools of children receiving special education ser-
vices during the 2001–2002 or 2002–2003 school years (or
both years). One site (Pennsylvania) screened a limited subset
of children’s special education records after parental authori-
zation to review the records.
For children with a previously documented classification of
an ASD, limited abstraction and review of evaluation records
was conducted. This limited (or “streamlined”) review based
on data obtained from MADDSP ASD surveillance indicated
that 98% of children aged 3–10 years with a previous ASD
diagnosis and 99% of children with previous autism eligibil-
ity for special education services satisfied the surveillance cri-
teria for having an ASD (1). The streamlined abstraction
included demographic and school service data, psychometric
test results, developmental history, and evaluation summaries
but excluded verbatim descriptions of behaviors associated with
autism; this review was employed by 12 of the 14 sites (all
except South Carolina and West Virginia). On the basis of
local diagnostic practices (3), each site chose one of the three
following scenarios to qualify a record for limited abstraction:
1) a record that documented a previous diagnosis of an ASD
(i.e., autistic disorder, PDD-NOS, or Asperger disorder) as
indicated by a corresponding ICD-9 (19) code or a written
diagnosis; 2) a record that documented a previous diagnosis
of “autistic disorder” as indicated by a corresponding ICD-9
code or a written diagnosis; or 3) a record that documented
that the child had been previously served in a special educa-
tion program under an autism eligibility category. All other
records that were not consistent with the criteria for stream-
lined abstraction were fully abstracted, including an abstrac-
tion of verbatim descriptions of behaviors predetermined to
be associated with an ASD. For all abstracted records, infor-
mation from multiple sources was combined into one com-
posite summary for each child.
Clinician Review
The clinician review process has been described previously
and consists of systematic classification of behaviors and case
status by qualified reviewers (1,13). Before clinician review,
interrater reliability was established among reviewers accord-
ing to standards, and only clinicians that met reliability stan-
dards were permitted to assign case status. Continuing
interrater reliability checks were conducted on a random
sample of 15% of fully abstracted records. These were scored
independently by a second reviewer. For all sites, the percent
of agreement for final case definition was acceptable (79%–
100%; Kappa = 0.55–1.00) (3).
For records that underwent limited abstraction because of a
previously documented ASD classification, children were con-
sidered to meet the ASD case definition on the basis of the
previously documented diagnosis unless 1) conflicting infor-
mation was noted in the record, 2) the reviewer needed addi-
tional information, or 3) the record indicated that an ASD
had been ruled out as a diagnosis. In those circumstances, a
full abstraction was performed, and the case was reviewed again
by the clinician reviewer. Data abstracted were reviewed and
scored by an ASD clinician reviewer according to a coding
guide on the basis of DSM-IV-TR criteria (2). Any statement
of general developmental concerns or delays in the areas of
social skills, language, or symbolic play at age <3 years was
scored, as were indications of behavioral regression or a pla-
teau in skill development. Descriptions of associated features
(e.g., odd responses to sensory stimuli, or abnormalities in
eating, drinking, or sleeping) also were coded.
Analytic Methods
The race/ethnicity of each child was determined from infor-
mation contained in the source records or, if not located in the
source file, from birth certificates (if available). Period preva-
lence estimates were calculated using as the denominator the
number of children aged 8 years residing in the surveillance
area according to the National Center for Health Statistics
(NCHS) vintage 2004 postcensal population estimates for July
1, 2002 (15). NCHS datasets provide estimated population
counts by county, single year of age, race, Hispanic origin, and
sex. Poisson approximation to the binomial distribution was
used to calculate 95% confidence intervals (CIs) for prevalence
(20). Race- or ethnicity-specific rates used five categories:
non-Hispanic white, non-Hispanic black, Hispanic, Asian/
Pacific Islander, and American Indian/Alaska Native. Preva-
lence results are reported per 1,000 children aged 8 years. Chi-
square tests were used to compare prevalence estimates within
and across sites within the 2002 surveillance year, and rate
ratios were used to compare prevalence changes within each
site from the years 2000 and 2002 (21,22). A maximum p value
of <0.05 was used for all tests of statistical significance.
The majority of sites considered the same broad criteria of
eligible children (i.e., ICD-9 codes and categories of educa-
tional exceptionality). However, seven sites (Alabama, Arkan-
sas, Georgia, North Carolina, South Carolina, Utah, and
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Wisconsin) reviewed records for additional ICD codes
because they also were conducting surveillance for other
developmental disabilities or because they added locally used
codes that might have identified additional cases of ASDs. To
facilitate an evaluation of the potential effect on ASD preva-
lence of reviewing health records for children with ICD-9 codes
requested by certain sites, the number of children who were
identified solely on the basis of those additional codes were
identified (3).
Two sites (Arizona and New Jersey) had a few school districts
in their entire surveillance area that did not participate.
Because school records were critical to case ascertainment and
those districts represented clearly defined geographic bound-
aries, final geographic study areas were finalized by removing
these school districts from the surveillance area. Children who
resided in nonparticipating school districts were subtracted from
the denominator and, if a case was ascertained at a health source,
it also was not included in the site’s numerator. Because the
NCHS postcensal population estimates were available only at
the county level (15), enrollment data from nonparticipating
school districts were used to curtail denominators. School
enrollment data were obtained from the U.S. Department of
Education’s National Center for Education Statistics (23).
Enrollment counts of students in third grade during the
2002–03 school year were noted to differ from NCHS
postcensal population estimates (15), which was attributed pri-
marily to children being enrolled out of the customary grade
for their age, in private schools, or home-schooled. Because these
differences varied by race and sex within the applicable coun-
ties, enrollment counts were adjusted by compiling data for all
districts within each county, stratifying by race and sex, and
comparing to NCHS postcensal counts. This provided an
adjustment factor for each race-sex stratum on the basis of its
variance from the corresponding NCHS estimate for that
county. The appropriate adjustment factor was then applied to
the stratified enrollment counts for each nonparticipating dis-
trict, and the adjusted counts were subtracted from the NCHS
postcensal estimates used for each county’s denominator.
At each site, certain education and health records could not
be located for review, and at three sites (Colorado, Maryland,
and North Carolina), certain schools in the area elected not
to participate. These schools did not represent clearly defined
geographic boundaries, so they could not be excluded from
the final surveillance area as was the case when entire districts
did not participate. Therefore, an analysis of the effect of these
missing records on case ascertainment was conducted. All
children initially identified for screening were first stratified
by two factors highly associated with final case status: infor-
mation source (education only, health only, or both types of
sources) and the presence or absence of either an ASD ICD-9
code or autism special education eligibility. The potential
number of cases missed because of missing records was esti-
mated under the assumption that within each of these six strata,
the proportion of children with missing records who would
ultimately be confirmed as ASD cases would have been
similar to that of children with no missing records.
Results
Total Prevalence Estimates
In 2002, across the 14 sites, total prevalence of ASDs in
children aged 8 years ranged from 3.3 (95% confidence inter-
val [CI] = 2.7–3.9) to 10.6 (CI = 9.5–11.9) per 1,000 chil-
dren (Table 2). The overall mean prevalence was 6.6 (CI =
6.3–6.8) per 1,000 children. Of the 14 sites, 12 were clus-
tered in a tighter range (5.2–7.6 per 1,000 children), and these
rates did not differ from each other significantly. However,
Alabama’s rate (3.3 per 1,000 population) was significantly
(p<0.001) lower than all other sites’ rates, and New Jersey’s
rate (10.6 per 1,000 population) was significantly (p<0.0001)
higher than all other sites’ rates.
Sources of Case Ascertainment
and Effects on Prevalence
 Sites varied in the proportion of children aged 8 years whose
records were abstracted in their population, ranging from 0.7%
in Wisconsin to 2.2% in Colorado, with the majority of sites
ranging from 1.0% to 1.8%. ASD prevalence was correlated
with the type of data source (p<0.05) (Figure 1). The weighted
average ASD prevalence for sites that relied solely on health
records to identify ASD cases was significantly lower (5.1 per
1,000 children aged 8 years; CI = 4.7–5.5) than that of sites
that relied on both education and health records (7.2; CI =
6.9–7.5) (p<0.0001). Three of the four sites that had limited
or no access to special education records (Alabama, Pennsyl-
vania, and Wisconsin) had the lowest three estimates of ASD
prevalence (Table 2). Pennsylvania obtained authorization from
only 15% of parents with children aged 8 years who were
receiving special education services to review their special edu-
cation records. The review of this sample yielded 17 addi-
tional cases. Thus, 85% of potential records were not reviewed,
and the number of potential cases from these records is
unknown. The prevalence of ASDs in one site (Missouri) with-
out access to special education records was higher than in six
of the sites that had full access to both health and education
records. No statistically significant variability in ASD preva-
lence was observed between nine of the 10 sites (range: 5.9–
7.6) with access to both school and health records (Table 2).
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Only the estimated prevalence in New Jersey (10.6 per 1,000
population) was significantly different (p<0.0001).
The percentage of ASD cases identified exclusively from
school sources varied from zero in sites without access to spe-
cial education records to nearly 85% in Arizona (Figure 2).
Similarly, the percentage identified only at health sources
ranged from <10% in Arizona, Georgia, and New Jersey to
100% in the sites without access to school records.
Prevalence by Race or Ethnicity
and Sex
For multiple sites, ASD prevalence also varied to a certain
extent by race and ethnicity (Table 2). In 10 sites, prevalence
was higher among non-Hispanic white children than among
non-Hispanic black children, but this difference was statisti-
cally significant (p<0.05) for only five sites (Georgia, Mis-
souri, New Jersey, Pennsylvania, and Wisconsin). In all sites
with prevalence estimates for Hispanic children, prevalence
was lower for Hispanic than for non-Hispanic white children;
this difference was statistically significant (p<0.05) for six sites
TABLE 2. Estimated prevalence* of autism spectrum disorders (ASDs) among children aged 8 years, by site and race/ethnicity —
Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2002
Total Total                                   Prevalence
no. in no. White, Black,
study with Overall† non-Hispanic non-Hispanic Hispanic AI/AN§ A/PI¶
Site  area ASDs Rate (95% CI**) Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
Sites with access
only to health
records
Alabama 35,472 116 3.3 (2.7–3.9)†† 3.3 (2.6–4.1) 3.4 (2.4–4.8) 1.9 (0.5–7.7) —§§ —
Missouri¶¶ 28,049 205 7.3 (6.4–8.4) 7.7 (6.5–9.0)*** 4.7 (3.4–6.5)*** 1.8 (0.3–13.0) — 7.1 (2.7–19.0)
Pennsylvania 21,061 111 5.3 (4.4–6.4) 7.6 (5.7–10.2)***††† 4.2 (3.2–5.6)*** 4.7 (2.8–8.0)††† — 1.2 (0.2–8.2)
Wisconsin 35,126 181 5.2 (4.5–6.0) 5.9 (5.0–6.9)***††† 3.7 (2.5–5.5)*** 0.3 (0.0–2.1)††† 5.2 (0.7–36.8) 3.8 (1.4–10.1)
Sites with access
to both education
and health records
Arizona 45,113 280 6.2 (5.5–7.0) 7.7 (6.7–8.9)††† 6.3 (3.8–10.5) 3.4 (2.6– 4.5)††† 3.1 (1.0–9.6) 2.6 (0.8–8.0)
Arkansas 36,472 251 6.9 (6.1–7.8) 7.4 (6.5–8.6) 5.8 (4.3–7.8) 2.9 (1.3– 6.4) 3.5 (0.5–24.7) —
Colorado 11,020 65 5.9 (4.6–7.5) 6.4 (4.8–8.5)††† 6.4 (2.9–14.3) 2.0 (0.7–5.3)††† 14.9 (2.1–106.0) 6.3 (2.0–19.6)
Georgia 44,299 337 7.6 (6.8–8.5) 8.9 (7.7–10.4)***††† 6.8 (5.7– 8.0)*** 4.6 (3.0–7.1)††† — 5.0 (2.7–9.3)
Maryland 29,722 199 6.7 (5.8–7.7) 7.0 (5.8–8.3) 6.2 (4.9–7.8) 1.4 (0.2–9.7) — 3.2 (1.0–9.9)
New Jersey 29,748 316 10.6 (9.5–11.9)†† 12.5 (10.7–14.6)*** 7.7 (6.0–9.9)*** 9.7 (7.7–12.3) — 14.0 (9.2–21.2)
North Carolina 20,725 135 6.5 (5.5–7.7) 6.4 (5.2–8.0) 7.2 (5.4–9.6) 4.10 (2.0– 8.6) 12.5 (1.8–88.7) 1.9 (0.3–13.7)
South Carolina 23,191 140 6.0 (5.1–7.1) 6.0 (4.8–7.6) 5.5 (4.2–7.1) 4.4 (1.4–13.6) — 4.5 (0.6–32.0)
Utah 26,108 196 7.5 (6.5–8.6) 8.0 (6.9–9.3)†† 5.5 (1.4–22.0) 4.4 (2.6– 7.2)††† — 2.2 (0.6–8.8)
West Virginia 21,472 153 7.1 (6.1–8.4) 6.8 (5.7–8.0) 6.4 (2.9–14.2) — — —
Source: Population data were obtained from CDC’s National Center for Health Statistics vintage 2004 postcensal population estimates (13).
* Per 1,000 children aged 8 years.
† All children are included in the total regardless of race or ethnicity. The total also includes children for whom race/ethnicity was unknown. Because of limited sample sizes,
results for Asians/Pacific Islanders and for AI/ANs are not presented. Because of the lack of an appropriate denominator, data for multiracial children and those of other
races/ethnicities are not presented.
§ American Indian/Alaska Native.
¶ Asian/Pacific Islander.
** Confidence interval.
†† Alabama and New Jersey prevalence are each significantly different from all other sites (p<0.001 and p<0.0001, respectively).
§§ No children were identified in this racial/ethnic population.
¶¶ Only Missouri data are presented from the Missouri/Illinois site as a result of limited numbers in Illinois.
*** Black-white prevalence ratio significantly different within site (p<0.05).
††† White-Hispanic prevalence ratio significantly different within site (p<0.05).
FIGURE 1. Prevalence* and percentage† of autism spectrum
disorders (ASDs) among children aged 8 years, by type of
data source — Autism and Developmental Disabilities
Monitoring Network, 14 sites, United States, 2002
* Per 1,000 children aged 8 years (R2 = 0.334, p = 0.03).
†Of children with ASDs identified by health sources only.
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(Arizona, Colorado, Georgia, Pennsylvania, Utah, and Wis-
consin). Prevalence estimates were lower for Hispanic chil-
dren than for non-Hispanic black children, except for New
Jersey, where prevalence was higher among Hispanic children
(9.7 per 1,000 population; CI = 7.7–12.3) than among non-
Hispanic black children (7.7 per 1,000 population; CI = 6.0–
9.9) (Table 2). Overall, population and case numbers were
too limited and CIs too wide to provide reliable prevalence
estimates for Asians/Pacific Islanders or American Indians/
Alaska Natives (Table 2).
A consistent finding in all sites was significantly higher
(p<0.0001) prevalence of ASDs among males than among
females (Table 3). Prevalence among males ranged from 5.0
per 1,000 population (CI = 4.1–6.2) in Alabama to 16.8
(CI = 14.9–19.0) per 1,000 population in New Jersey. Female
prevalence ranged from 1.4 per 1,000 population (CI = 0.9–
2.1) in Alabama to 4.0 per 1,000 population (CI = 3.1–5.2)
in New Jersey. When male-to-female prevalence was compared,
observed sex ratios ranged from 3.4:1.0 in Maryland, South
Carolina, and Wisconsin to 6.5:1.0 in Utah.
Special Education Eligibility
For the 10 sites that had full access to school records, the
percentage of children with ASDs receiving special education
services through public schools was determined. This percent-
age was >60% in all 10 sites and >80% in eight sites (Table 4).
The percentage of children with ASDs that received special
education services with an autism special education eligibility
ranged from 31% in Colorado to 74% in Maryland (Table 4).
TABLE 3. Estimated prevalence* of autism spectrum disorders
(ASDs) among children aged 8 years, by site and sex — Autism
and Developmental Disabilities Monitoring Network, 14 sites,
United States, 2002
Prevalence Male-to-
Males Females female
Site Rate (95% CI†) Rate (95% CI) ratio§
Sites with access
only to health
records
Alabama 5.0 (4.1–6.2) 1.4 (0.9–2.1) 3.6:1
Missouri 11.3 (9.7–13.2) 3.1 (2.3–4.3) 3.6:1
Pennsylvania 8.7 (7.1–10.6) 1.8 (1.2–2.9) 4.8:1
Wisconsin 7.9 (6.7–9.3) 2.3 (1.7–3.1) 3.4:1
Sites with access
to both health
and education
records
Arizona 10.1 (8.8–11.4) 2.2 (1.7–2.9) 4.6:1
Arkansas 10.7 (9.3–12.3) 2.9 (2.2–3.8) 3.7:1
Colorado 9.9 (7.6–12.9) 1.7 (0.9–3.2) 5.8:1
Georgia 12.4 (11.0–13.9) 2.6 (2.3–3.4) 4.8:1
Maryland 10.2 (8.7–11.9) 3.0 (2.3–4.1) 3.4:1
New Jersey 16.8 (14.9–19.0) 4.0 (3.1–5.2) 4.2:1
North Carolina 10.6 (8.9–12.8) 2.1 (1.4–3.2) 5.0:1
South Carolina 9.2 (7.6–11.1) 2.7 (1.9–3.9) 3.41
Utah 12.7 (11.0–14.8) 2.0 (1.3–2.9) 6.5:1
West Virginia 11.0 (9.2–13.12) 3.0 (2.1–4.2) 3.7:1
Source: Population data were obtained from CDC’s National Center for
Health Statistics vintage 2004 postcensal population estimates (13).
* Per 1,000 children aged 8 years.
†Confidence intervals.
§All male-to-female ratios rounded to one decimal place; all male-to-
female ratios significantly different within sites (p<0.0001).
FIGURE 2. Percentages of children aged 8 years with autism
spectrum disorders, by data source — Autism and Develop-
mental Disabilities Monitoring Network, 14 sites, United
States, 2002
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TABLE 4. Number and percentage of children aged 8 years
with autism spectrum disorders (ASDs) receiving special
education services and with autism eligibility, by site — Autism
and Developmental Disabilities Monitoring Network, United
States, 2002
Receiving Receiving
special special education
education services with
Total no. services  autism eligibility†
Site* with ASDs No. (%) No. (%)
Arizona 280 271 (96.8) 107 (39.5)
Arkansas 251 206 (82.1) 120 (58.3)
Colorado 65 59 (90.8) 18 (30.5)
Georgia 337 309 (91.7) 211 (68.3)
Maryland 199 122 (61.3) 90 (73.8)
New Jersey 316 309 (97.8) 131 (42.4)
North Carolina 135 121 (89.6) 68 (56.2)
South Carolina 140 102 (72.9) 48 (47.1)
Utah 196 166 (84.7) 82 (49.4)
West Virginia 153 134 (87.6) 63 (47.0)
* With access to both education and health records.
†Primary special education eligibility category only.
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impairment (Figure 4), and in four sites (Arizona, Arkansas,
South Carolina, and Utah), females were significantly (p<0.05)
more likely than males to have cognitive impairment. Differ-
ences between females and males were not statistically signifi-
cant in Colorado, Georgia, or North Carolina. Only in South
Carolina did more than half of males with ASDs have IQ scores
of <70, and only in North Carolina did fewer than half of
females with ASDs have IQ scores of <70. North Carolina was
also the only site that had a higher proportion of males than
females with IQ scores of <70. Across all sites, females were more
likely than males (58.2% and 41.8%, respectively) (p<0.001) to
have IQ scores in the range of cognitive impairment.
Developmental Characteristics
In all sites, more than half (range: 51.0%–91.4%) of chil-
dren meeting surveillance criteria for ASDs by age 8 years had
documented developmental concerns before age 3 years
(Table 5). The most commonly documented early develop-
mental concern was for language skills, followed by social con-
cerns. Documented developmental concerns with imaginative
play were least common. The median age of earliest reported
ASD diagnosis identified in a child’s record ranged from 49
months in Utah to 66 months in Alabama (Table 6). The
percentage of children with a documented indication of
regression (i.e., loss of previously acquired skills in social, com-
munication, play, or motor areas) ranged from 13.8% in Colo-
rado to 31.6% in Utah, and the median age of regression
ranged from 18 months in New Jersey, North Carolina, Utah,
and Wisconsin to 33 months in Pennsylvania (Table 6). The
percentage with indications of plateau (i.e., lack of continued
development without clear evidence of regression) ranged from
2.4% in Arkansas to 12.8% in Utah.
Comparison Between 2000 and 2002
Prevalence Estimates
Six sites had determined ASD prevalence previously using
the ADDM Network methodology in 2000. Rate ratios were
calculated to compare changes in prevalence during 2000–2002.
ASD prevalence was stable for four sites (Arizona, Maryland,
New Jersey, and South Carolina) and increased 17% in Geor-
gia (p = 0.06) and 39% in West Virginia (p<0.01) (Table 7).
Methodological Results
New Jersey had the most evaluations available for review
per child identified as having an ASD, with the median num-
ber of evaluations abstracted for each child ranging from two
in Maryland to eight in New Jersey among children with ASDs,
Previously Documented Classification
of ASD
Children with a previously documented ASD classification
included those who received special education services under
an autism special education exceptionality category or those
with a diagnosis of ASD documented in their health or edu-
cation records, or both. In all sites, the prevalence estimated
on the basis of having a previous diagnosis of an ASD was
lower than that estimated on the basis of the ADDM Net-
work Surveillance methodology (Figure 3).
Cognitive Functioning
Data regarding cognitive functioning are reported for seven
sites in which >80% of children had psychometric test results.
The proportion of children in these sites with ASDs who also
had cognitive impairment (defined as having intelligence quo-
tient [IQ] scores of <70) ranged from 33.1% in Utah to 58.5%
in South Carolina (average: 44.6%) (Figure 4). In six sites
(Arizona, Arkansas, Colorado, Georgia, South Carolina, and
Utah), females were more likely than males to have cognitive
FIGURE 3. Overall prevalence* of autism spectrum disorders
(ASDs) among children aged 8 years and prevalence of ASDs
among children with a previously documented ASD
classification,† by source type and order of ASD prevalence
— Autism and Developmental Disabilities Monitoring (ADDM)
Network, 14 sites, United States, 2002
* Per 1,000 population.
†Children were classified as having a previously documented ASD
classification if they had 1) received a diagnosis of autistic disorder,
pervasive developmental disorder (PDD)-not otherwise specified,
Asperger syndrome, PDD, or ASD by a qualified professional that was
documented in an evaluation record or 2) had special education services
under an autism eligibility category.
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and from one in Maryland to five in New Jersey among chil-
dren without ASDs. Of the seven sites requesting additional
ICD-9 codes while conducting surveillance for other disabili-
ties, three sites (Alabama, Arkansas, and Utah) did not iden-
tify any additional cases, two sites (Georgia and North
Carolina) identified <1% of their ASD cases exclusively on
the basis of the additional codes, and Colorado and Wiscon-
sin identified 1.5% and 3.3% respectively of their ASD cases
exclusively from the additional codes. On the basis of these
findings, sites that used only the core ICD-9 codes for ASD
case finding might have increased their case yield by 0–3%, if
additional codes were requested.
TABLE 5. Percentage of children with autism spectrum disorders for whom developmental concerns were noted before age 3
years and median age at which concerns were noted — Autism and Developmental Disabilities Monitoring Network, 14 sites,
United States, 2002
General concern Social Language Imaginative play
Median age Median age Median age Median age
Site % (mos) % (mos) % (mos) % (mos)
Sites with access only to health
records
Alabama 91.4 <24 33.6 <36 85.3 <24 14.7 <36
Missouri 75.1 <24 22.9 <24 67.8 <24 10.7 <24
Pennsylvania 77.5 <24 23.4 <36 63.1 <24 15.3 <36
Wisconsin 86.2 <24 37.0 <24 77.3 <24 16.0 <24
Sites with access to both education
and health records
Arizona 82.5 <24 31.8 <36 75.4 <24 4.3 <36
Arkansas 84.9 <24 28.7 <36 77.7 <24 6.0 <36
Colorado 73.8 <36 35.4 <36 60.0 <36 27.7 <36
Georgia 79.5 <24 24.9 <36 70.3 <24 8.6 <36
Maryland 62.3 <24 20.6 <36 51.3 <24 9.5 <36
New Jersey 89.6 <24 43.4 <36 83.2 <24 25.6 <36
North Carolina 80.0 <24 29.6 <36 69.6 <24 15.6 <36
South Carolina 87.1 <36 32.9 <36 77.1 <36 10.7 <36
Utah 88.8 <24 51.5 <24 77.0 <24 21.9 <36
West Virginia 51.0 <36 16.3 <36 42.5 <36 10.5 <36
* Includes only sites with cognitive functioning data for >80% of cases.
FIGURE 4. Percentages of children aged 8 years with and without cognitive impairment, by intelligence quotient (IQ) score,
site, and sex — Autism and Developmental Disabilities Monitoring Network, 14 sites,* United States, 2002
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TABLE 7. Prevalence* of autism spectrum disorders (ASDs) — Autism and Developmental Disabilities Monitoring Network, six
sites, United States, 2000 and 2002
Total ASD prevalence      2000-to-2002
2000 2002  rate ratio Prevalence change
Site Rate (95% CI†) Rate (95% CI) Rate (95% CI) 2000–2002
Arizona 6.5 (5.8–7.3) 6.2 (5.5–7.0) 1.0 (0.8–1.1) -0.3
Georgia 6.5 (5.8–7.3) 7.6 (6.8–8.5) 1.2 (1.0–1.4)§ +1.1§
Maryland 6.3 (5.6–7.4)¶ 6.7 (5.8–7.7) 1.1 (0.9–1.3) +0.4
New Jersey 9.9 (8.9–11.3) 10.6 (9.5–11.9) 1.1 (0.9–1.3) +0.7
South Carolina 6.3 (5.4–7.4) 6.0 (5.1–7.1) 1.0 (0.8–1.2) -0.3
West Virginia 5.1 (4.2–6.1)¶ 7.1 (6.1–8.4) 1.4 (1.1–1.8)** +2.0**
* Per 1,000 children aged 8 years.
† Confidence interval.
§ Not statistically significant at p=0.06.
¶ ASD prevalence reported for Maryland and West Virginia are the adjusted rates calculated to account for having a single year of education records that
were screened for these two sites compared with 2 years of education records for the other four sites.
** Statistically significant at p<0.01.
TABLE 6. Median age at earliest diagnosis with autism spectrum disorder (ASD) and proportion and median age of children with
a confirmed ASD at age 8 years and for whom developmental regression or plateau was noted in records — Autism and
Developmental Disabilities Monitoring Network, 14 sites, United States, 2002
Age of earliest documented
ASD diagnosis in record Regression* Plateau†
Median age Range Median age Median age
Site (mos) (mos) (%) (mos) (%) (mos)
Sites with access only to health
records
Alabama 66 10–101 25.0% 24 4.3% 14
Missouri 56 20–106 17.6% 24 4.4% 18
Pennsylvania 58 24–94 18.0% 33 3.6% 18
Wisconsin 54 11–104 25.4% 18 7.7% 15
Sites with access to both education
and health records
Arizona 63 20–101 18.6% 24 6.4% 21
Arkansas 59 21–106 17.1% 22 2.4% 18
Colorado 62 12–100 13.8% 24 7.7% 24
Georgia 58 23–103 17.5% 24 3.9% 22
Maryland 60 21–105 14.1% 24 4.5% 24
New Jersey 53 15–101 21.8% 18 11.4% 18
North Carolina 53 21–99 19.3% 18 3.7% 18
South Carolina 64 22–103 19.3% 20 3.6% 18
Utah 49 18–102 31.6% 18 12.8% 18
West Virginia 54 20–106 15.7% 24 0 0
* Includes any mention of a loss of skills that the child previously had in social, communication, play, or motor areas at any age in a child’s evaluation
records.
† Includes any mention of a leveling off of skills (i.e., lack of continued development but no clear loss of skills) in social, communication, play, or motor
areas at any age in a child’s evaluation records.
Discussion
The ADDM Network surveillance method applies a stan-
dardized case definition to detailed behavioral data collected
from health and education records of children evaluated for
various developmental concerns. In the 14 areas studied in
2002, ASD prevalence estimates for children aged 8 years
ranged from 3.3 per 1,000 population in Alabama to 10.6
per 1,000 population in New Jersey. The other 12 sites had a
more restricted range (5.2–7.6 per 1,000 children aged 8 years
identified with an ASD). The average prevalence estimate of
6.6 per 1,000 population (CI = 6.3–6.8) for all sites and 7.2
per 1,000 population (CI = 6.9–7.5) from sites with access to
education information were consistent with the upper end of
the prevalence (5.8–6.7 per 1,000 population) from recent
epidemiologic studies using active population screening and
clinical case confirmation in children (1,14,24–35). The higher
rate identified in New Jersey was consistent with rates of 11.6
and 12.1 per 1,000 population recorded in two other recent
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studies (36,37) indicating that approximately 1% of children
were identified with an ASD. The lower rate of ASDs in chil-
dren aged 8 years in Alabama and the higher rate in New
Jersey, compared with the other 12 sites, indicates the impor-
tance of continued evaluation of cross-site variation and trends
in prevalence in the United States.
ASD Prevalence by Race/Ethnicity
and Sex
The majority of sites had sufficient populations to evaluate
differences in ASD prevalence for non-Hispanic white and
non-Hispanic black children. A trend was noted for non-
Hispanic white children to have slightly higher prevalence
estimates than non-Hispanic black children. This difference
was statistically significant in three of the four sites for which
access to health records only was possible (Missouri, Pennsyl-
vania, and Wisconsin), but in only two of the 10 sites (Geor-
gia and New Jersey) for which access to health and education
records existed. In sites for which access to both health and
education records existed, a statistically significant overall dif-
ference was noted by race, with more non-Hispanic white
children (average: 7.7 per 1,000 population) than non-
Hispanic black children (average: 6.5 per 1,000 population)
identified as having an ASD. With the exception of New Jersey,
prevalence for Hispanic children was lower than for non-
Hispanic white or non-Hispanic black children. For Ameri-
can Indian/Alaska Native or Asian/Pacific Islander children,
great variability was noted in prevalence of ASDs across sites,
with small case and population numbers in each population
contributing to highly imprecise site estimates. Differences in
the racial or ethnic distribution of ASDs for populations other
than non-Hispanic white and non-Hispanic black children
should be interpreted with caution. Although racial differ-
ences are often reported not to be significant in children with
ASDs (38), few studies have been based on large, diverse popu-
lations (1). These data indicate that ASD prevalence might
vary by race/ethnicity; however, reasons for the differences
need further investigation. Sociodemographic factors might
influence both who gets evaluated for developmental concerns
and how those concerns and behaviors are documented (39).
Further analysis is needed of the sociodemographic features
of the children identified with ASDs and identification pat-
terns in evaluation records.
All sites identified more males than females with an ASD,
with sex-specific ASD prevalence for males ranging from 5.0
in Alabama to 16.8 in New Jersey, and for females from 1.4 in
Alabama to 4.0 in New Jersey. Male-to-female ratios ranged
from 3.4:1 in Maryland, South Carolina, and Wisconsin to
6.5:1 in Utah. These ratios were similar to results reported
previously (38,40–44). The average ASD prevalence across
the 10 sites with access to both health and education sources
indicated that ASD prevalence was 11.5 per 1,000 popula-
tion for males and 2.7 per 1,000 population for females,
resulting in a 4.3:1 ratio. Investigation is warranted concern-
ing the possibility of differential identification and documen-
tation of ASD symptoms within and across sites for males
and females. Overall, these data confirm that ASDs affect males
more than females in all areas, and variation in this phenom-
enon is not wide. The data also highlight the importance of
considering sex differences in etiologic investigations of ASDs.
Cognitive Functioning
Epidemiologic studies of ASDs commonly include estimates
of intellectual functioning, often reporting the proportion of
all ASD cases with mental retardation and occasionally inves-
tigating differences according to diagnostic subtype. Other
population-based studies have reported sex differences in
intellectual functioning among children with ASDs, with cer-
tain indication of the male-to-female ASD prevalence ratio as
decreasing with greater levels of impairment in intellectual
functioning (1,38). The current ADDM Network findings
indicate that females aged 8 years with ASDs were signifi-
cantly more likely than males to score in the range of cogni-
tive impairment on their most recent psychometric test. In
the seven sites (Arizona, Arkansas, Colorado, Georgia, North
Carolina, South Carolina, and Utah) with sufficient intellec-
tual functioning data available, only one (South Carolina)
reported more than half of the males with ASD with scores in
the cognitively impaired range, and only North Carolina
reported fewer than half of the females with ASDs with scores
in the cognitively impaired range. In addition, North Caro-
lina was the only site to have a higher proportion of males
with cognitive impairment than females; however, the num-
ber of females represented by this comparison was low in North
Carolina. Four of the remaining sites (Arizona, Arkansas, South
Carolina, and Utah) had a significantly higher proportion of
females with cognitive impairment compared with males
(p<0.05). Overall, more than half of females (58%) and less
than half of males (42%) had scores in the cognitively
impaired range.
Although the ADDM Network methodology does not pro-
vide diagnostic subclassification of all children identified with
ASDs, the current findings are consistent with other epide-
miologic studies showing a higher proportion of males diag-
nosed with Asperger disorder and PDD-NOS, and a lower
proportion of children with these diagnostic subtypes scoring
in the range of cognitive impairment (1,39–44).
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Developmental Characteristics
Children with a previously documented ASD classification
included those who had received special education services
under an autism special education eligibility and those with a
clear diagnosis of ASD documented in the education or health
source records, or both. Across the sites for which education
information was accessible, the proportion of children identi-
fied with ASDs receiving special education services with an
autism eligibility ranged from 31% in Colorado to 74% in
Maryland. The prevalence estimates derived for children aged
8 years with ASDs who had a previously documented ASD
classification ranged from 2.2 per 1,000 population in Ala-
bama to 7.4 per 1,000 population in New Jersey. For all sites,
the prevalence calculated from having a previous classifica-
tion of ASD was lower than the ADDM Network prevalence
of having an ASD. These results indicate that if an ASD is
identified on the basis only of a documented diagnosis or eli-
gibility for autism on record, prevalence would have been
underestimated by as much as 30%.
An experienced clinician using standardized methods can
reliably diagnose autism in children as young as age 2 years
(45). Across the ADDM Network sites, the majority of chil-
dren aged 8 years had diagnostic evaluations indicating gen-
eral developmental concerns before age 3 years. Concerns in
language development were generally noted at younger ages
than concerns in social or imaginative play. However, age at
first documented ASD diagnosis in the reviewed records var-
ied greatly, from 10 months in the areas studied in Alabama
to as late as 8 years, 10 months in the areas studied in Arkan-
sas, Missouri, and West Virginia. These data confirm an ear-
lier report (46) that a significant lag exists between early
concerns and actual identification of an ASD as reported in
records in multiple areas of the country, contributing to
potentially significant delays in intervention. Given the ben-
efit of early intervention (47), identification of an ASD at
earlier ages in the United States is essential to ensure that chil-
dren receive optimal early intervention services. CDC has been
working with caregiver and professional groups to improve
the early recognition of developmental concerns and to
improve referral for further evaluation and intervention with the
“Learn the Signs. Act Early.” public awareness campaign (48).
Children with an ASD can experience a loss of develop-
mental skills or a plateau in development, or both. Across all
ADDM Network sites, 2%–13% of children had a plateau in
development that was significant enough to be reported in a
developmental evaluation. In addition, 14%–32% of the chil-
dren were noted to have lost developmental skills at young
ages, usually before age 2 years. The majority of ADDM Net-
work sites reported developmental regression below the pro-
portion reported from another study (49) that suggested that
25%–33% of children with an ASD are reported to experi-
ence a loss of developmental skills by the second year of life.
However, the distinction between a loss of skills and a plateau
in skills has not been made in previous studies. Reliance on
existing records might not adequately ascertain this feature
because certain providers might not evaluate or document the
potential for developmental regression. Therefore, these
results should be considered a minimal estimate of plateau
and regression among ASD cases.
Changes in ASD Prevalence During
2000–2002
Six sites (in Arizona, Georgia, Maryland, New Jersey, South
Carolina, and West Virginia) had previously determined the
prevalence of ASD using the ADDM Network methodology
in the year 2000 (14). Prevalence was stable for four of these
sites (Arizona, Maryland, New Jersey, and South Carolina).
In one site (West Virginia), ASD prevalence was significantly
higher (p<0.01) in 2002 than in 2000, and the prevalence in
Georgia appeared to be increasing, but the change was not
statistically significant (p<0.06). New Jersey’s ASD prevalence
was higher than all other sites in both years, but it did not
increase significantly from 2000 to 2002 (among children born
in 1992 and 1994, respectively). Whether the disproportion-
ate increase in the West Virginia ASD prevalence was attrib-
utable to a true increase in the prevalence of the condition in
that state compared with that in the other five areas or was an
artifact of the record-review methodology is difficult to deter-
mine. Because case status is confirmed by descriptions in
records, greater detail in records for the 2002 study year would
potentially provide more data that would be needed to con-
firm cases in this surveillance year than in 2000. An informal,
qualitative assessment of differences in the quality and quan-
tity of information contained in evaluation records across sites
indicated that the quality and amount of information con-
tained in West Virginia’s evaluation records improved over
time. However, other factors relating to differential prevalence
cannot be ruled out. Future ADDM Network surveillance
years will add a rating of the quality of information contained
in the records to help evaluate the role that changing quality
of records might play in determining prevalence. Further analy-
sis of prevalence in sites with multiple prevalence estimates
will be reported in future site-specific analyses and reports.
Strengths, Limitations, and Factors
Influencing Prevalence Estimates
A strength of the ADDM Network is the consistency in
data collection and case determination methods across sites
and surveillance years. The ADDM Network surveillance
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methodology requires standardized training of abstractors and
clinician reviewers, ongoing monitoring for quality assurance,
and standardization of methods to identify and confirm
potential cases and conduct data analysis. The level of detail
in the abstracted records from multiple sources, coupled with
careful, standardized clinician reviews, improves upon previ-
ous estimates based solely on administrative records or single-
source surveillance. With the addition of access to both health
and education evaluation sources in all sites, the prevalence
estimates from this methodology might more closely approxi-
mate true prevalence.
Although the ADDM Network method has strengths, cer-
tain limitations exist. Direct reevaluation of each child to
determine case status is not part of a records-based approach
to surveillance, thereby minimizing the burden on children
and their families. Children identified with an ASD have had
case status validated through record review and concordance
between having a previous classification of an ASD and being
identified as having an ASD is high. However, case identifica-
tion has not been validated independently against a standard
diagnostic reevaluation of each child. A validation study
that includes independent examination of children is cur-
rently underway at the Georgia site.
Multiple factors can contribute to the quality of data and,
ultimately, to prevalence estimates (14,50). Variability in preva-
lence among sites is likely attributable to differences in access
to records at all sources, evaluation practices, and the result-
ing level of detail in records. The majority of ADDM Net-
work sites included as sources of records public schools and
major developmental disabilities evaluation and treatment
centers serving their respective surveillance areas. The major-
ity of sites did not include private schools, charter schools,
and clinical providers or service centers with small numbers
of clients (3). The resulting effect on prevalence estimates was
difficult to quantify, but might have contributed in some man-
ner to underestimation of prevalence. With the exception of
New Jersey’s higher prevalence, prevalence estimates were con-
sistent across nine of the 10 sites with access to education
evaluations. Prevalence was much more variable among the
sites with access only to health evaluations, ranging from 3.3
per 1,000 population in Alabama to 7.3 per 1,000 popula-
tion in Missouri. Although evaluations at education sources
were not reviewed in Missouri, evaluation records were
reviewed at regional developmental assessment and interven-
tion centers within the Missouri Department of Mental
Health. These sources might have served as a source of
detailed ASD case information unique to that site and could
have contributed to the Missouri site having the highest ASD
prevalence among the sites that did not review education
records. For sites with access to education information, a sub-
stantial proportion of persons with ASDs (15%–82%) would
not have been identified without education data. In addition,
a proportion of those cases identified from a combination of
education and health data (range: 15%–68% of cases) also
might have been missed if the information from education
sources was unavailable. Thus, access to information from both
health and education sources appears essential for obtaining
accurate prevalence and to the success of records-based ASD
monitoring in the United States. This emphasizes both the
importance of including schools in surveillance activities and
of public schools in the evaluation and treatment of children
with disabilities.
Sources of evaluations by public service agencies doubtlessly
provide information on children representing the broad
sociodemographic spectrum because all children who show
educational impairments are entitled to an evaluation and to
a free, appropriate education (50). Because the ADDM Net-
work method screens records of children evaluated or quali-
fied for special education for features of ASDs, regardless of
eligibility, this method should eliminate the bias of identify-
ing children with ASD that have additional access to private
healthcare sources for evaluation and treatment of develop-
mental concerns. However, further evaluation of potential
variability in the quality of information required to confirm
ASD case status is needed because there could be systematic
variation in information on children’s developmental features
by type of source or by sociodemographic characteristics of
children.
A crucial aspect of a records-based surveillance system is
being able to actually locate the evaluation record that con-
tains the diagnostic and behavioral information to confirm
case status. Sensitivity analyses conducted by all sites deter-
mined that files that were eligible for review but not located
contributed to an underestimate in prevalence from 0.4% to
20%. Because of unfound files, prevalence might have been
underestimated by <5% in eight sites (Alabama, Arizona,
Arkansas, Colorado, Georgia, New Jersey, North Carolina,
and Wisconsin), by 6%–8% in three sites (Missouri, Utah,
and West Virginia), by up to 15% in two sites (Maryland and
Pennsylvania), and as high as 20% in South Carolina. The
number of the records abstracted at each ADDM Network
site could have influenced prevalence estimation (3). A larger
pool of children in special education or with evaluations for
clinical services could increase the probability of identifying
cases; however, sites that abstracted a higher proportion of
records per population did not have correspondingly higher
prevalence estimates. For example, New Jersey had the high-
est prevalence, but it did not have a significantly greater pro-
portion of the population identified for special education or a
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greater proportion of records screened and abstracted than
other sites.
The majority of sites considered the same broad criteria of
eligible children (on the basis of ICD-9 codes and categories
of educational exceptionality). However, six sites reviewed
records for additional ICD codes because they were also con-
ducting surveillance for other developmental disabilities, or
because they added locally used codes. Those extra codes might
have identified a few more cases of ASDs, but given the initial
breadth of the review criteria, the effect of this activity was
likely minimal.
A common explanation for increases in ASDs over time has
been that changes have occurred in the level of community
and professional awareness about the symptoms of ASD and
the application of an ASD diagnosis to a wider range of
symptomology (10,38,44,51). Because the ADDM Network
screens children who have been evaluated for special educa-
tion or diagnostic services for multiple reasons, the primary
way in which increased awareness could account for differ-
ences in prevalence across sites, or over time in the same site,
is if either differences occurred in who is evaluated for devel-
opmental concerns or changes occurred in how the social and
other ASD behaviors were documented in the evaluation
records. However, across the ADDM Network sites with
access to both education and health records, no clear relation
existed among sites that identified more students in their popu-
lations for special education and the prevalence of ASDs.
Using ADDM Network methods in areas in which more chil-
dren were classified as eligible to receive special education for
any reason did not result in identification of more children
with an ASD. However, children with an ASD who have not
been evaluated or qualified for services documented by the
health or education sources might still exist, and this could
have underestimated prevalence. For children with evaluation
records, the quality of the information in the records might
have been a factor. A qualitative review of West Virginia’s
records during 2000–2002 indicated that more behavioral
descriptions existed to confirm case status for the later study
year. Also, New Jersey had more evaluations per child and a
qualitative review of information indicated more detailed
behavioral descriptions. However, if higher prevalence in New
Jersey was caused by better symptom documentation in evalu-
ation records, that would suggest that prevalence in other sites
might have been underestimated, which would indicate that
ASDs could be more common then previously thought. For
the 2006 surveillance year, ADDM Network surveillance has
included a rating to classify the quality of information in the
records.
Another factor possibly contributing to variation in preva-
lence among sites was differential migration in and out of the
surveillance area. The prevalence estimates provided in this
report are period prevalence based on residency in the study
area during 2002. The effects of migration patterns could not
be evaluated, but the proportion of children with ASDs who
were born in the study areas ranged from 28% in Colorado to
57% in Arizona and Georgia and 85% in Alabama, indicat-
ing potentially significant variation in migration patterns across
sites. For Colorado, 29% of children identified as having ASDs
were born in a neighboring county to the study area counties,
indicating potential differential migration around metropoli-
tan Denver based on having a child with a developmental
disability.
Conclusion
This report has described multiple sources of variability that
might be responsible for differences in observed prevalence
across study sites. Although certain sources of variability were
not easily quantifiable, the inclusion or exclusion of educa-
tion data was one known source of variability that appeared
to have a direct effect on prevalence estimates. Other known
and unknown sources of error most likely contributed to an
underestimate of ASD prevalence and have been examined
elsewhere (3). Despite these limitations, the ADDM Network
has provided a comprehensive, population-based monitoring
program for ASDs in the United States. Implementation of
the ADDM Network requires ongoing collaboration with data
sources at each site for access to records. The standardized
protocol yielded prevalence estimates that were stable across
multiple sites in the country in which access to both educa-
tion and health records was possible. Although the initial start-
up of each site took multiple years, future reports of ASD
prevalence should be more timely. In the majority of sites for
which 2 years of surveillance data were available, prevalence
remained stable; however, a trend existed toward increased
prevalence in Georgia and a significant (p<0.01) increase was
observed in West Virginia. As the protocol is implemented
using the same methods in future years, the ADDM Network
will continue to monitor temporal trends in ASD prevalence
in specific areas of the United States. Prevalence estimates also
will be used to plan policy and educational and intervention
services for persons with ASDs. Continuing to monitor the
prevalence of ASDs in the United States is important, and
more in-depth analyses of case identification by source type,
quality of information, and sociodemographic factors should
be conducted to improve understanding of these disorders.
ADDM Network data provide a solid baseline prevalence with
which future estimates can be compared. They also confirm
that ASDs are more common then previously thought and
are conditions of urgent public health concern.
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Abstract
Problem: Autism spectrum disorders (ASDs) encompass a spectrum of conditions, including autistic disorder; perva-
sive developmental disorders, not otherwise specified (PDD-NOS); and Asperger disorder. Impairments associated
with ASDs can range from mild to severe. In 2000, in response to increasing public heath concern regarding ASDs,
CDC established the Autism and Developmental Disabilities Monitoring (ADDM) Network. The primary objective
of this ongoing surveillance system is to track the prevalence and characteristics of ASDs in the United States. ADDM
data are useful to understand the prevalence of ASDs and have implications for improved identification, health and
education service planning, and intervention for children with ASDs. Because complete, valid, timely, and representa-
tive prevalence estimates are essential to inform public health responses to ASDs, evaluating the effectiveness and
efficiency of the ADDM methodology is needed to determine how well these methods meet the network’s objective.
Reporting Period: 2002.
Description of System: The ADDM Network is a multiple-source, population-based, active system for monitoring
ASDs and other developmental disabilities. In 2002, data were collected from 14 collaborative sites. This report
describes an evaluation conducted using guidelines established by CDC for evaluating public health surveillance sys-
tems and is based on examination of the following characteristics of the ADDM Network surveillance system: simplic-
ity, flexibility, data quality, acceptability, representativeness, sensitivity, predictive value positive (PVP), timeliness,
stability, data confidentiality and security, and sources of variability.
Results and Interpretation: Using multiple sources for case ascertainment strengthens the system’s representativeness,
sensitivity, and flexibility, and the clinician review process aims to bolster PVP. Sensitivity and PVP are difficult to
measure, but the ADDM methodology provides the best possible estimate currently available of prevalence of ASDs
without conducting complete population screening and
diagnostic clinical case confirmation. Although the sys-
tem is dependent on the quality and availability of infor-
mation in evaluation records, extensive quality control
and data cleaning protocols and missing records assess-
ments ensure the most accurate reflection of the
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records reviewed. Maintaining timeliness remains a challenge with this complex methodology, and continuous effort is
needed to improve timeliness and simplicity without sacrificing data quality. The most difficult influences to assess are
the effects of changes in diagnostic and treatment practices, service provision, and community awareness. Information
sharing through education and outreach with site-specific stakeholders is the best mechanism for understanding the
current climate in the community with respect to changes in service provision and public policy related to ASDs,
which can affect prevalence estimates.
Public Health Actions: These evaluation results and descriptions can be used to help interpret the ADDM Network
2002 surveillance year data and can serve as a model for other public health surveillance systems, especially those
designed to monitor the prevalence of complex disorders.
Simplicity
The simplicity of a public health surveillance system refers
to both its structure and ease of operation. The simplicity of
an autism surveillance system is limited by the variability of
ASD signs and symptoms and methods of diagnosis (3,4).
Impairments associated with ASDs can range from mild to
severe. More subtle features at the less severe end of the spec-
trum can remain undiagnosed as they are found in children
with better communication skills and average to above-
average intellectual functioning. Severity also can change as
the child ages or in response to effective intervention. No
observable physical attribute or clinical test can define case
status, nor can cases be identified at a single point in time or
type of data source. A diagnosis of an ASD is made on the
basis of a constellation of behavioral symptoms rather than
on biologic markers; therefore, surveillance case ascertainment
requires standardized interpretation of behavioral evaluations
from records at both education and health facilities. A broad
range of diagnoses over multiple years must be reviewed to
ensure complete case finding because children rarely receive a
specific diagnosis of an ASD before age 2–3 years, with a more
stable diagnosis by age 8 years (5–7). The ADDM Network
common methodology (Figure 1) uses a record-based surveil-
lance system dependent on access to education, health, and
service agencies (e.g., public schools, state health clinics and
diagnostic centers, hospitals, and other providers for children
with developmental disabilities [DDs]) to identify cases and
ensure unduplicated case counting. The process for case
ascertainment occurs in two phases: 1) identification of
potential cases through record screening and abstraction and
2) review of abstracted information by an ASD clinician
reviewer to determine whether behaviors described in the child’s
evaluations are consistent with the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-
IV-TR) (8) criteria for autistic disorder, PDD-NOS (including
atypical autism), or Asperger disorder (1,9).
Accurate collection and review of detailed evaluation infor-
mation from multiple data sources is time consuming, and the
Introduction
Autism spectrum disorders (ASDs) encompass a spectrum
of conditions, including autistic disorder; pervasive develop-
mental disorders not otherwise specified (PDD-NOS); and
Asperger disorder. Impairments associated with ASDs can
range from mild to severe. ASDs are of increasing public health
concern because the number of children receiving services for
these conditions is growing. Despite the need to understand
ASDs better, few data are available concerning the prevalence,
characteristics, and trends of these conditions. In 2000, CDC
established the Autism and Developmental Disabilities Moni-
toring (ADDM) Network to track the prevalence and charac-
teristics of ASDs in the United States. The ADDM network is
a multiple-source, active, population-based surveillance sys-
tem that reviews developmental records at educational and
health sources and employs a standardized case algorithm to
identify ASD cases. ADDM data are useful to understand the
prevalence of ASDs and can promote improved identifica-
tion, health and education service planning, and intervention
for children with ASDs.
Complete, valid, timely, and representative prevalence esti-
mates are essential to inform public health responses to ASDs.
Evaluation of the effectiveness and efficiency of the ADDM
methodology, described in detail elsewhere (1), is necessary to
understand how well the methods meet the network’s objec-
tive. This report examines the ADDM Network methodol-
ogy employed by 14 collaborative sites that collected data for
the 2002 surveillance year and evaluates the validity and com-
pleteness of prevalence estimates and the effect of sources of
variability on intersite prevalence differences. This evaluation
was conducted using guidelines established by CDC for evalu-
ating public health surveillance systems and includes exami-
nation of the following characteristics of the ADDM Network
surveillance system, including simplicity, flexibility, data qual-
ity, acceptability, representativeness, predictive value positive,
sensitivity, timeliness, stability, data confidentiality and secu-
rity, and sources of variability (2).
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* International Classification of Diseases, Ninth Revision.
† Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.
§ ADDM sites conducting surveillance of mental retardation (MR), cerebral palsy (CP), hearing loss, and vision impairment request codes specific to
these disorders in addition to those for ascertainment of autism spectrum disorders (ASDs).
¶ To improve timeliness, North Carolina did not review special education records of children with a speech and language impairment (SLI) exceptionality.
A sample of these children indicated that this decision had a minimal effect on North Carolina prevalence. Georgia did not review special education
records of children with a SLI, behavior disorder (BD) or learning disorder (LD) exceptionality. Georgia reviewed all records at the Psychological
Services Department affiliated with the State Department of Special Education. The records of all children with a comprehensive psychological evalu-
ation in special education are located at the psychological services department capturing children with BD and LD exceptionalities. A sample of children
in SLI showed that this decision had a minimal effect on Georgia prevalence.
** Alliance for Research in Child Health Epidemiology.
†† All sites conducting surveillance for CP are conducting linkage of cases with vital statistics death certificates. If feasible, sites conducting ASD and MR
surveillance also conducted this death certificate linkage. For sites that completed this linkage, no ASD cases were identified.
FIGURE 1. Surveillance methodology flowchart — Autism and Developmental Disabilities Monitoring (ADDM) Network
Analyze data and generate and disseminate
reports to data sources, stakeholders, and
scientific community for feedback and
distribution of information for public health action
Submit de-identified data to ADDM pooled
dataset
Link to vital statistics birth certificate data††
Implement final data cleaning procedures
Complete abstraction for each child; records
reviewed by trained, reliable clinician
reviewers to assign final case status
Review and abstract individual records in field
and enter data directly into ARCHE database
Identify multiple health and education sources in community that evaluate, educate, and
treat children with developmental disabilities and obtain agreements for record review
Request and receive data from
educational sources for all special
education exceptionalities¶
Request and receive data from
health sources according to select
ICD-9* and DSM-IV billing codes§†
Import all data into ARCHE** database linking
children's records across multiple sources to
a common tracking key per child
Replicate ARCHE database at each site
weekly and merge abstracted data from
multiple sources for a given child into one
record; run reports for data cleaning after
each replication
Conduct ongoing quality control (QC) on
decision to abstract for a 10% sample of
records that were reviewed but not abstracted
and on a 10% sample of all abstracted records
for critical data fields; take both samples for
each abstractor at each site (see Figure 3)
Conduct ongoing quality control on a 10%
sample of pending cases for critical clinician
review fields (see Figure 3)
lack of electronic records at the majority of data sources
requires additional tasks (e.g., coordination with agencies, travel,
record abstraction, and data entry). Time-tracking data collected
systematically by all abstractors in Arizona indicated that
abstractors spent an average of 55 hours to review or abstract,
or both, 100 records. Survey data from six sites indicated that a
single clinician review required an average of 20 minutes under
the streamlined protocol (see Predictive Value Positive) and 47
minutes under the routine protocol. Quality assurance proce-
dures implemented throughout data collection add time, effort,
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and complexity to the overall system. However, a detailed, labor-
intensive approach might be the only way to produce accurate
prevalence estimates for this complex behavior disorder.
Flexibility
The flexibility of a public health surveillance system refers
to its ability to accommodate changes in information needs
or operating conditions with little additional time, personnel,
or allocated funds. The flexibility of the ADDM Network
methodology allows the system to add new data sources, col-
lect additional data elements, and incorporate the evolving
science of developmental disabilities (e.g., new case defini-
tions). The ADDM methodology can adapt to changes in data
elements and case definitions between surveillance years; how-
ever, retrospective changes would be limited to data already
collected. ADDM Network methods rely on, and are limited
by, the availability and quality of data in evaluation records
and access to those records. ADDM Network surveillance
activities have been expanded to monitor other developmen-
tal disabilities, including hearing loss, vision impairment,
mental retardation and cerebral palsy simultaneously. ADDM
Network data also can be linked to external datasets (e.g., state
birth certificate files, birth defects surveillance and newborn
screening data, and complementary instruments to track
children’s medication prescriptions).
Data Quality
Data quality refers to the completeness and validity of a
surveillance system. The amount and quality of information
available from the record of an existing evaluation varies within
and across ADDM Network sites and is difficult to quantify.
Variability in state and local regulations, regional practices for
evaluating children, and the number of providers visited can
affect the number and types of evaluations available. For
example, in certain states, a single record is sufficient to
obtain autism eligibility for special education, but other states
(e.g., New Jersey) often use multiple multidisciplinary evalu-
ations. A qualitative comparison indicates that both the
amount and quality of relevant information in records in New
Jersey were greater than those at other sites. Case ascertain-
ment is influenced by the rate of referral of children for devel-
opmental evaluation and by the sensitivity of the evaluation
in detecting and recording signs and symptoms of ASDs. The
ADDM Network methodology maximizes data quality by
evaluating the completeness of record review, maintaining
reliability in data collection and coding, and cleaning the data
fields. Although these measures are taken to ensure the accuracy
of data capture, the validity of the conclusions is dependent on
the data in the evaluation records reviewed by project staff.
Evaluating the Completeness of Record
Review
Eligible records identified by data sources but not located
or available for access (e.g., located at a nonparticipating
school) were classified as missing. The nature of missing records
might have been systematic across multiple data sources within
each ADDM site, but missing records probably were
nonsystematic within an individual data source. A sensitivity
analysis was conducted to evaluate the effect of missing records
on prevalence (see Sensitivity).
Maintaining Reliability in Data Collection
and Coding Methods
The reliability of data collection and coding was measured
against standards to ensure effective initial training, identify
ongoing training needs, and adhere to the prescribed method-
ology. These efforts support the reliability of ADDM data by
quantifying potential error caused by inconsistent data collec-
tion and coding procedures. Initial and ongoing quality con-
trol reliability methods follow a set protocol (Figures 2 and 3).
Cleaning Data Fields
The ADDM Network implements regular, extensive, and
systematic data cleaning to identify inconsistencies in reviewed
and abstracted data and resolve conflicts that arise. Missing
race and ethnicity information was obtained through linkage
with state vital birth records.
Acceptability
The acceptability of a surveillance system is demonstrated
by the willingness of persons and organizations to participate
in surveillance system activities. The project’s overall success
was dependent on acceptance of the ADDM Network by
health and education sources of each site, as these sources were
needed to identify cases of ASDs. Voluntary agreements (e.g.,
memoranda of understanding or contracts) were established
between ADDM Network sites and health and education
sources that authorized site personnel to review and collect
information from health or education records (Table 1). ASDs
were reportable conditions at three sites (Colorado, Utah, and
West Virginia), giving these sites public health authority to
review and collect data from health-care facilities with no sepa-
rate agreements required. At six sites (Arkansas, Maryland,
North Carolina, South Carolina, Utah, and West Virginia),
all targeted health sources participated. At eight sites (Alabama,
Arizona, Colorado, Georgia, Missouri, New Jersey, Pennsyl-
vania, and Wisconsin), at least one targeted health facility did
not participate. The project’s acceptability was lower among
education sources; four sites were unable to gain access to edu-
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cation facilities or had minimal access (Alabama, Missouri,
Pennsylvania, and Wisconsin). At six sites (Arizona, Arkan-
sas, Colorado, Maryland, New Jersey, and North Carolina),
certain schools or entire districts in their surveillance area
elected not to participate. In four sites (Georgia, South Caro-
lina, Utah, and West Virginia), school participation was com-
plete. Lack of participation by education sources caused four
sites (Arizona, Colorado, New Jersey, and North Carolina) to
redefine their surveillance areas after data collection had started.
Project coordinators were surveyed to determine their percep-
tion of the factors that influenced acceptability by health and
education sources. The most common factors reported were
privacy and confidentiality concerns of the sources, including
the Health Insurance Portability and Accountability Act
(HIPAA), time or resources required from the sources, and
the Family Education Rights and Privacy Act (FERPA). Project
staff distributed literature to parents and stakeholders at mul-
tiple forums and attended conferences to increase reporting
of developmental concerns to providers, understanding of the
importance of population-based surveillance of ASDs, and
awareness of ASD among parents and community members.
Representativeness
Correct interpretation of surveillance data requires evalua-
tion of the representativeness and accuracy of the surveillance
system in describing the occurrence of ASDs in the popula-
tion. The ADDM Network 2002 surveillance year included
14 sites that accounted collectively for 10.1% of the U.S. popu-
lation aged 8 years. Because participating sites were selected
through a competitive federal award process and not specifi-
cally to be representative of the entire U.S. population, ADDM
FIGURE 2. Flowchart for quality control for initial reliability — Autism and Developmental Disabilities Monitoring Network
no >80% correct
• Conducted at CDC at start of each surveillance year
• Conducted at site for staff hired later
• Trainer reviews and discusses details described in relevant training manuals
• Trainer demonstrates proper data collection and coding procedures using
sample records
• Trainees independently apply these procedures on practice records
• During final training session, trainees resolve questions and discrepancies
arising from their review of these practice records
• Finally, trainees are given a set of deidentified records to review independently
• 16 records to review for correct decision to
abstract
• Number of qualifying records to abstract into
the database
• Scored according to a “gold standard”
abstraction
• Abstraction training quiz
• Errors discussed with abstractors individually
• Shadow experienced abstractor for 2 weeks
• Independent review and abstraction
• Training continues for the first month
• Work sampled during this period by quality-
control auditor to ensure quality
Abstractors
no >80% correct
no Same accuracy
standards as above
met by all reviewers
• 10 records to review
• At each site, the first 10 records are
independently reviewed by all of the sites'
clinician reviewers
• Reviewers meet to determine consensus
• Records assigned for independent review
Clinician reviewers
no >80% correct for all
coded behaviors
>
>
85% correct for
examiner diagnosis
90% for assigned
case status
Initial training of abstractors and clinician reviewers
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Network results cannot be used as a basis for estimating the
national prevalence of ASDs. Two national surveys designed as
random samples of the U.S. noninstitutionalized population
estimated prevalence of ASDs from parental reports of autism
diagnosis among children aged 6–8 years to be 7.5 and 7.6
cases per 1,000 population, respectively (10). Although gener-
ated using a different methodology, these estimates were simi-
lar to ADDM estimates, thereby providing external validation.
The denominator is another determinant of representative-
ness. The 2002 surveillance year sites used data from the
National Center for Health Statistics (NCHS) vintage 2004
postcensal bridged-race population estimates for July 1, 2002,
to obtain counts by sex and race and ethnicity of the number
of children aged 8 years (11). NCHS bridged postcensal popu-
lation estimates are produced by the U.S. Census Bureau
immediately after a decennial census. However, trends noted
between two decennial censuses can vary substantially from
trends forecast in the postcensal estimates (12). For this rea-
son, annual postcensal estimates are updated after the subse-
quent decennial census, and intercensal estimates are produced.
Once the 2010 census has been completed and intercensal
estimates are published for 2002 and beyond, the ADDM
Network will recalculate previously reported prevalence esti-
mates to evaluate the effect of any postcensal and intercensal
differences within and across sites. Using postcensal estimates
rather than intercensal estimates results has been demonstrated
to overestimate the prevalence of a disorder; the extent might
vary by race/ethnicity (13,14). The effect of postcensal and
intercensal differences might not be significant for the 2002
surveillance year but will become important as the ADDM
Network collects data in subsequent surveillance years and
trends are examined. No better alternative has been developed
for calculating prevalence for all ADDM Network sites than
NCHS data.
FIGURE 3. Flowchart for quality control for ongoing reliability — Autism and Developmental Disabilities Monitoring Network
no >80% correct on
critical data fields
Ongoing reliability
• 10% random sample of reviewed (but not
abstracted) records drawn for re-review
stratified by
– abstractor
– data source
• 10% of random sample of abstracted recalls
by each abstractor drawn for re-review
• Review is complete
• Sites provide deidentified records for review
• A “gold standard” abstraction is established
for each record by CDC
• Results are discussed by conference call
Local abstractor evaluation
no 100% correct
by abstractor
Local evaluationclinician review
• Blinded interrater reliability
• 15% sample of fully abstracted records
resent for review
• Areas of concern identified
• Consensus established
no >80% agreement for
coded behaviors
>
>
85% correct for
examiner diagnosis
90% for assigned
case status
• Reviewed for decision to abstract
Multisite abstractor reliability evaluation Multisite clinician review reliability evaluation
• All clinician reviewers across sites review a
record in common each month
• Individual results are compared and
discussed by conference call
• Review is complete
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Predictive Value Positive
Predictive value positive (PVP) is the probability that a child
whose condition is consistent with the surveillance case defi-
nition actually has the disease or condition under surveillance.
A clinical diagnosis of an ASD requires intensive in-person
examination of a child and often interview with the primary
caregivers. Clinical confirmation of all cases identified using
ADDM Network methods is resource prohibitive. The
ADDM Network multiple-source, active record review meth-
odology provides a feasible approach to population-based
monitoring of ASDs. However, the ADDM methodology
relies on past diagnoses, special education eligibilities, and
behaviors described in children’s health or education records
to classify a child as having an ASD. The lack of a “gold stan-
dard” in-person standardized clinical assessment to validate
these methods introduces the possibility of false-positive cases.
The validity of the ADDM Network methodology for
determining case status is under assessment in a study by the
Georgia ADDM Network site using clinical examinations to
calculate the proportion of false-positives among confirmed
ASD cases using ADDM Network methods. In 2002, the
University of Miami was funded as an ADDM Network
grantee to validate its ASD surveillance methods. Results from
this validation project indicate that the concordance between
a previously documented ASD diagnosis and the ADDM
Network record review case status (97%) was greater than that
of a screening with the Social Communication Questionnaire
(87% at a cut-off test score of 13 points) (Marygrace Yale
Kaiser, University of Miami, unpublished communication,
2006). Although not compared directly to the results of a clini-
cal examination, these data lend support to reasonable PVP
of the ADDM case-status determination.
Across the 14 ADDM Network sites for the 2002 surveil-
lance year, 57%–86% of children classified by the ADDM
Network methodology as having confirmed cases of ASDs had
a previous ASD diagnosis or special education classification
of autism. Past assessments of ADDM Network methodol-
ogy, together with another report of 93% (15), support the
assumption that PVP for this subgroup of cases is high. A
study noting a relatively high (36%) false-positive rate of
diagnoses reported in education records in the United King-
dom examined a limited sample (n = 33) and was difficult to
compare with the ADDM Network system (16). Conversely,
across sites, 14%–43% of children confirmed in the ADDM
Network system as having an ASD had not received an ASD
TABLE 1. Characteristics of participating data sources and record review process, by site — Autism and Developmental Disabilities
Monitoring Network, 14 sites, United States, 2002
No. No. No. children No. No. children No.
participating records for whom records records for whom records children reviewed
Characteristic data sources requested were requested abstracted were abstracted for ASDs*
Sites with access to
health records
Alabama† 24 2,769 2,147 866 584 318
Missouri-Illinois§ 23 3,972 3,149 672 434 403
Pennsylvania¶ 124 1,049 796 330 252 252
Wisconsin† 18 4,404 3,897 716 558 239
Sites with access to
health and education
records
Arizona§ 36 4,437 4,185 555 475 475
Arkansas**†† 293 7,547 5,908 1,632 1,137 525
Colorado§ 24 2,721 2,387 518 415 415
Georgia§§ 43 5,747 3,784 2,042 1,245 687
Maryland¶¶ 9 4,747 4,013 421 311 311
New Jersey§ 62 2,758 2,415 519 431 428
North Carolina** 32 3,980 3,518 810 602 369
South Carolina** 70 4,280 3,601 863 679 293
Utah** 31 5,941 4,549 1,010 566 409
West Virginia 60 4,383 4,093 295 200 200
* Autism spectrum disorders.
† Monitored ASDs and cerebral palsy.
§ Represents records and children identified as a part of original surveillance area of Arizona, Colorado, Missouri-Illinois, and New Jersey. When limited
to children in the final surveillance area, the number of children abstracted for ASDs were 474 in Arizona, 239 in Colorado, 363 in Missouri, and 425 in
New Jersey.
¶ Pennsylvania had access to a limited number of school records through a parental consent pilot study.
** Monitored ASDs and mental retardation.
†† Large number of individual school districts.
§§ Monitored ASDs, mental retardation, cerebral palsy, hearing loss, and vision impairment.
¶¶ School districts were large and few in number.
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classification previously. Suspicion of an ASD was noted for
6%–19% of these children, leaving 7%–31% with no previ-
ous mention in the records of an ASD. ADDM Network
methods were designed to identify children with noted
behaviors consistent with ASDs but who lacked a formal
diagnosis; however, this group might have had the greatest
potential for false-positive classification.
One final issue affecting the sensitivity and specificity of the
ADDM Network methodology for the 2002 surveillance year
is the implementation of a streamlined abstraction and review
protocol for children with a previous ASD diagnosis. In an ear-
lier evaluation of these methods, 97% of children aged 8 years
who were identified with a previous ASD classification ulti-
mately were confirmed by surveillance clinician reviewers as
having ASDs (CDC, unpublished data, 1996). To improve time-
liness, 12 of the 14 sites adopted a streamlined abstraction and
review protocol for such children. The criteria used in deter-
mining which records qualified for streamlining varied by site,
and the percentage of cases ascertained using the streamlined
protocol ranged from 19% in Colorado to 68% in Georgia (see
Sensitivity). Because streamlined abstraction involves limited
data collection of behavioral descriptions beyond those required
to determine case status, the 2002 ADDM Network sites were
unable to evaluate the proportion of persons whose cases would
not have been confirmed on the basis of a full review of the
behavioral descriptions in the children’s records. However, data
from the four sites that implemented full abstraction and
review for the 2000 surveillance year and streamlined abstrac-
tion and review for the 2002 surveillance year indicated that
the potential effect of false-positives attributable to the stream-
lined protocol might have been minimal (weighted average: 6%).
PVP has been improved by selectively screening high-risk
segments of the population, including children receiving spe-
cial education services in public schools or children with
select International Classification of Diseases, Ninth Edition
(ICD-9) and DSM-IV-TR billing codes related to develop-
mental disabilities in health sources, or both (8,17).
Sensitivity
Prevalence of ASDs Detected by ADDM
Network Methods
The completeness of case ascertainment depends on the sen-
sitivity of the methodology to ascertain children with ASDs
in the population. To assess potential underascertainment,
quantitative or qualitative examinations (or both) were per-
formed to identify the effects of the number of home school
and private school children with ASDs; nonparticipating or
unidentified data sources; abstractor error; missing records;
sites requesting additional ICD-9 and DSM-IV-TR codes; and
differing streamlining criteria.
Private school or home school children whose conditions
were consistent with the case definition might have been missed
because site agreements with public schools did not include
access to information on children in nonpublic schools. Data
from a random weighted sample of U.S. children aged 4–17
years from the National Survey of Children’s Health (NSCH)
reported that 14.2% of children whose parents reported them
as having a past diagnosis of autism were attending private
schools, and 1.8% were home schooled (CDC, unpublished
data, 2006). Although such children were not identified sys-
tematically by ADDM Network methods through review of
public education records, a subgroup might have been identi-
fied through one or more health facilities at a given ADDM
Network site.
Efforts were made to identify all sources that had evaluated
children for ASDs. The project continually tracked new
examiners and facilities identified from children’s evaluation
histories to ensure that all potential data sources were pur-
sued. However, certain health and education facilities declined
to participate or were not identified by project staff (See
Acceptability). Using statistical capture-recapture techniques
to estimate the effect of this issue on prevalence was consid-
ered, but the assumption of independence would have been
violated, thereby invalidating that method. Therefore, a quan-
titative assessment could not be made of the extent to which
missing sources affected surveillance estimates.
Results from ongoing quality control activities were used to
evaluate the accuracy of the decision made by abstractors to
review the record and final case determination assigned by
clinician reviewers at each site. The range of percentage of
concordance regarding the decision to abstract between the
quality-control auditor and abstractor at each site ranged from
87% in Georgia to 100% in North Carolina and West Vir-
ginia. For clinician review, the percentage of concordance on
final case definition ranged from 79% in Utah to 100% in
New Jersey (Table 2). Although quality control results for cer-
tain sites were below the established threshold, records for all
abstractors and clinician reviewers that fell below the thresh-
old were resampled until the thresholds were met. In addi-
tion, the secondary clinician review process provided assurance
that the primary clinician review results are an underestimate
of true agreement on final case status. The clinician review
process also serves to strengthen PVP as discordance on final
case status can result in over- or underascertainment.
To evaluate the effect of missing records on prevalence, all
children initially identified for screening from participating
sources at each site were classified into three groups: 1) all
Vol. 56 / SS-1 Surveillance Summaries 37
requested records located, 2) certain requested records not
located, and 3) no requested records located. The children
were further subdivided into six strata by type of data source
(education only, health only, or both) and specificity of ASD
screening criterion (presence of an ASD-specific ICD-9 or
DSM-IV-TR code or school eligibility, compared with all other
school eligibility, ICD-9, and DSM-IV-TR codes). Data were
analyzed assuming that within each type of source or ASD-
specific stratum, children with missing records would have
had the same likelihood of being identified as a confirmed
ASD case child, had their records been located, as children for
whom all records were available for review. These analyses
indicated that the possible effect of missing records on preva-
lence underestimation ranged from 0.4% in Wisconsin to 20%
in South Carolina (Table 2).
A standard basic list of ICD-9 and DSM-IV-TR codes
was reviewed for the 2002 surveillance year. However, sites
that also conducted surveillance for mental retardation
(Arkansas, Georgia, North Carolina, South Carolina, and
Utah); cerebral palsy (Alabama, Georgia, and Wisconsin); and
both hearing loss and vision impairment (Georgia) requested
additional ICD-9 codes. One site (Colorado) also requested
codes identified as important because of specific coding prac-
tices in the area. The proportion of additional cases identified
from these additional ICD-9 codes, assuming all records with
these unique codes would contribute to case status, ranged
from 0% in Arkansas to 5.0% in Wisconsin (Table 2). This
suggests that the additional codes would not have increased
prevalence estimates substantially.
The criteria used for determining which children qualified
for streamlining varied by site. Seven sites (Arizona, Arkansas,
Georgia, Maryland, Missouri, New Jersey, and Pennsylvania)
elected to streamline children with a primary school eligibil-
ity category of autism or a broad-spectrum ASD diagnosis,
whereas Utah based streamlining on autism eligibility but a
more restrictive diagnosis of autistic disorder. Four sites
TABLE 2. Measurable evaluation characteristics, by site — Autism and Developmental Disabilities Monitoring Network,* 14 sites,
United States, 2002
Ongoing abstractor Ongoing clinician Additional requested Streamlined
quality control reviewer quality control Missing records ICD-9 codes† records§
% concordance % concordance Estimated % Estimated % Estimated %
Site on decision to abstract on final case definition prevalence effect prevalence effect prevalence effect
Sites with access
to health records
Alabama 92% 91% -1.8% 0–+4.3% -3.4%
Missouri 97% 89% -8.1% ** -3.9%
Pennsylvania¶ 92% 92% -14.7% ** -9.9%
Wisconsin 98% 86% -0.4% +3.3–+5.0% -2.8%
Sites with access
to both health and
education records
Arizona 99% 86% -1.4% ** -0.7%
Arkansas †† 92% -3.9% 0 -3.6%
Colorado 99% 88% -1.4% +1.5–+4.6% -4.6%
Georgia 87% 93% -4.3% +0.9–+4.7% -3.6%
Maryland 94% 94% -14.8% ** -9.0%
New Jersey †† 100% -4.9% ** 0%
North Carolina§§ 100% 91% -4.8% +0.7% -5.9%
South Carolina 99% 81% -20.2% ** -4.3%
Utah †† 79% -7.8% 0–+0.5% -0.6%
West Virginia 100% 86% -6.1% ** -2.0%
* Estimates of the effect of each evaluation characteristic cannot be summed to calculate an adjusted prevalence estimate because the measures are not
mutually exclusive, other evaluation characteristics effecting prevalence were not quantifiable, and a significant overlap between the characteristics
presented might exist. All abstractors and clinician reviewers had to meet initial reliability standards before beginning record review; therefore, initial
quality control was completed at all sites.
† The lower bound of the range represents the effect of children who were identified exclusively from data sources with additional International Classifi-
cation of Diseases, Ninth Edition (ICD-9) codes, and the upper bound represents the effect of children with more than one data source for which one
data source had exclusively the additional ICD-9 code(s) and another source had an ICD-9 code on the common list. Whether the record from the data
source with the additional ICD-9 code list would have provided information to contribute to case confirmation is unclear.
§ Least conservative streamlining criteria were applied to all children abstracted at each site.
¶ Pennsylvania had access to a limited number of school records through a parental consent pilot study.
** Evaluation of this characteristic was not applicable to a given site because the site did not request additional ICD-9 codes.
†† Site did not conduct specific evaluation according to joint methods.
§§ North Carolina identified one child (0.7%) uniquely from data sources with additional ICD-9 codes and no children with more than one data source for which
one data source exclusively had the additional ICD-9 code(s) and another source had a common list ICD-9 code. Therefore, a range is not presented.
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(Alabama, Colorado, North Carolina, and Wisconsin) stream-
lined records only for children with an autistic disorder diag-
nosis. West Virginia and South Carolina did not implement
the streamlined protocol for the 2002 surveillance year. To
facilitate comparability between site prevalence estimates, given
this potential variability in ascertainment from using differ-
ent criteria for streamlining, the least conservative streamlin-
ing criteria were applied to all children abstracted at each site.
The effect on prevalence ranged from 0 in New Jersey to 9.9%
in Pennsylvania (Table 2).
Ability of ADDM Network Methods to Monitor
Changes in Prevalence
The use of consistent methods for case identification across
surveillance years enhances the ability of the ADDM Net-
work methods to detect changes in ASD prevalence over time.
However, a true increase in ASD population prevalence might
be difficult to distinguish from an increase attributable to
increases in provider awareness of ASDs, changes in service
provision regulations or diagnostic and treatment patterns, or
differences in the breadth and depth of behavioral informa-
tion in evaluation records. For example, between the 2000
and 2002 surveillance years, the prevalence of ASDs in West
Virginia increased 39%. A qualitative assessment of behav-
ioral descriptions contained in their site’s evaluations indicated
that improvements were made in the quality and amount of
information in evaluation records during this period which
might have contributed to the increase. Beginning with the
2006 surveillance year, the ADDM Network will begin rating
the quality of information in records to facilitate quantitative
evaluation of changes in the quality of information contained
in records and their effect on prevalence over time. Because
ADDM Network prevalence estimates do not rely solely on a
documented ASD diagnosis from a single source, they are less
likely to be affected by trends in specific usage of ASD diag-
noses as long as children with social, communication, and
behavioral symptoms continue to be evaluated by health or
education sources for treatment or services, or both.
Although ADDM Network methods are subject to these
challenges, recent studies have demonstrated that aggregate
administrative data (e.g., autism eligibility data from the U.S.
Department of Education) are not optimal for measuring
period prevalence or monitoring changes over time. The
ADDM Network’s multiple-source methodology produces
prevalence estimates with greater robustness to minimize clas-
sification bias than alternative available ASD prevalence mea-
sures (18–20).
Timeliness
The timeliness of the surveillance system is the speed of
progression from identifying data sources to releasing results.
The ADDM Network population-based surveillance system
can be resource and time intensive, particularly at its incep-
tion at a new site, as evidenced by the multitude of data sources
required for participation, high volume of records for review,
and abstraction and clinician review and time estimates previ-
ously reported for each step in the process (Table 1). Each site
must first identify potential sources for identification of
potential cases, obtain access to health and education records,
hire and train staff, and ensure that reliability thresholds for
abstractors and clinician reviewers are met. Although the
ADDM sites participating in the 2002 surveillance year rep-
resent multiple grant cycles, the estimated time required for
this surveillance year, from start of funding to reporting of
results, was approximately 3–4 years. Once the surveillance
system has been instituted at a site, these limitations to time-
liness are greatly reduced for future surveillance years.
As ADDM Network surveillance methods have evolved, the
time required to make data available has decreased. Multiple
surveillance years can now be conducted concurrently, and
clinician review has been restructured to increase efficiency.
In addition, case yield is evaluated from specific ICD-9 and
DSM-IV-TR codes to determine whether certain codes could
be omitted, thereby reducing the number of records to review
without decreasing prevalence estimates substantially. Data
management methods also have improved, reducing the time
from data collection to reporting of the results.
Stability
Stability is the reliability and availability of a surveillance
system consistently over time. Stability of the ADDM Net-
work system is promoted by the continuing technical support
and coordination provided by CDC, which maintains consis-
tency in methodology across sites. Computer and network
support provided by CDC minimizes time lost through com-
puter or other technical problems. Continuation of the
ADDM Network has been assured through a new 4-year grant
cycle for 2006–2010, and data collection for the 2004 and
2006 surveillance years are underway. Nevertheless, because
ADDM Network methods rely on administrative data, changes
in maintenance of records and classification and assessment
of children with ASDs over time might affect ADDM Net-
work stability.
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Data Confidentiality and Security
Although not a formal attribute of the guidelines for evalu-
ating public health surveillance systems, data confidentiality
and security must be assured. The ADDM Network employs
strict guidelines to maintain the highest level of data security
and confidentiality. All staff members receive intensive train-
ing concerning confidentiality policies and sign nondisclo-
sure agreements. The network employs enhanced protection
of computer files and maintains information technology
security procedures for the data collection instrument to
ensure that the data remain secure and confidential, includ-
ing Power On passwords, Windows 2000/XP/NT passwords,
MS Access Workgroup Security, and MS Access Encryption.
All backups of the ARCHE database are encrypted. Once the
surveillance year is completed, deidentified data are submit-
ted to the pooled dataset. Proposals to use the aggregate,
deidentified data are reviewed by the principal investigators
of the ADDM Network.
Sources of Variability Across ADDM
Network Sites
The ADDM Network is a multiple-site, collaborative net-
work using a common methodology. An important goal of
the network is to make meaningful comparisons of prevalence
across sites. Therefore, this evaluation assessed not only how
well the population prevalence of ASDs is measured within
each site but also how variations in the implementation of the
common methodology affected comparison of prevalence
across ADDM Network sites. Data collected previously using
ADDM Network methods indicated the importance of edu-
cation records in monitoring the prevalence of children with
developmental disabilities (9,21,22). The primary difference
between ADDM Network sites for the 2002 surveillance year
was the ability to access education records as 4 sites had very
limited or no access to education sources. The average preva-
lence for sites with access to both health and education sources
was significantly higher (p<0.0001) than that of sites with
access to health sources only (9).
All ADDM Network sites implemented a common meth-
odology to obtain ASD prevalence. Variability across sites in
specific aspects of the common protocol were introduced
through attempts to improve timeliness and conduct surveil-
lance of additional developmental disabilities, in addition to
the uncontrollable variability in facility evaluation practices.
Certain sources of variability are measurable for evaluation
(Table 2). These sources of variability are not mutually exclu-
sive and, therefore, cannot be summed to represent an
adjusted range of potential prevalence estimates across ADDM
Network sites. Moreover, these estimates are not a compre-
hensive list of all sources of overascertainment and under-
ascertainment because multiple influences that might have had
an effect on prevalence (e.g., quality of information in records
or proportion of children who were not evaluated at any
participating data source) were not quantifiable. Although
evaluation results indicate variability across sites in the imple-
mentation of the common methodology, site-specific preva-
lence estimates are regarded as complete, valid, and accurate,
and the results offer a reasonable method for comparing
intersite prevalence characteristics.
The approach to streamlined abstraction and the review of
additional ICD-9 billing codes varied slightly by site, as did
the degree of missing records. Although consistency strength-
ens a common methodology, diagnostic and billing practices
differed by data source within each site, and slight modifica-
tions to enhance the ability of a site to capture the true preva-
lence of ASD were expected. Although the quality of
abstraction and clinician review inevitably will vary within
and across sites, strict quality control protocols implemented
by each site enabled them to monitor the variability in quality
control and resolve problems quickly.
Conclusion
The ADDM Network is the only, active, ongoing, mul-
tiple-source surveillance system for tracking prevalence of
ASDs and other developmental disabilities in the United States.
Using multiple sources for case ascertainment strengthens the
system’s representativeness, sensitivity, and flexibility, and the
clinician review process aims to bolster PVP. Although sensi-
tivity and PVP are difficult to measure, ADDM methods pro-
vide the best estimate of the population prevalence of ASDs
short of conducting complete population screening and diag-
nostic clinical case confirmation. Although the system depends
on the quality and availability of information in evaluation
records, extensive quality control and data cleaning protocols
and assessment of missing records ensure the most accurate
reflection of the records reviewed. Maintaining timeliness
remains a challenge with this complex methodology; how-
ever, possibilities for streamlining to improve timeliness and
simplicity without sacrificing data quality continue to be
investigated. The effects of changes in diagnostic and treat-
ment practices, service provision, and community awareness
are the most difficult influences to assess.
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Information sharing through education and outreach with
site-specific stakeholders is the best mechanism for understand-
ing the current climate in the community with respect to
changes in service provision and public policy related to ASDs,
which can affect prevalence estimates. This evaluation can be
used to help interpret surveillance results and serve as a model
for other systems, especially those that monitor the prevalence
of complex disorders.
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